Arylpyridinone itk inhibitors for treating inflammation and cancer

ABSTRACT

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): 
     
       
         
         
             
             
         
       
         
         
           
             wherein Ar, R 2 , R 4 , R 5 , n and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Applications No. 61/931,484, filed Jan. 24, 2014, and 62/007,477, filed Jun. 4, 2014, the contents of each are hereby incorporated by reference.

BACKGROUND

1. Field

The present disclosure relates to new arylpyridinone compounds and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of ITK activity in a human or animal subject are also provided for the treatment diseases such as those caused by inflammation.

2. Description of Related Art

The Tec (tyrosine kinase expressed in hepatocellular carcinoma) family of tyrosine kinases (TFTK) consists of five family members: Tec, BTK (Bruton's tyrosine kinase), BMX (bone marrow kinase on the X chromosome also known as ETK), RLK (resting lymphocyte kinase also known as TXK) and ITK (interleukin-2 inducible T cell kdsinase, also known as EMT and TSK). These kinases are central to the regulation of hematopoietic cell biology and more specifically the development and activity of lymphocytes and myeloid cells (Horwood et al. (2012) Int. Rev. Immunol. 31, 87-103; Boucheron et al. (2012) Int. Rev. Immunol. 31, 133-154; Koprulu et al. (2009) Crit. Rev. Immunol. 29, 317-333). The TFTK have structural similarities to other non-receptor tyrosine kinases while exhibiting some family specific motifs resulting in a diversity of domain structures associated with complex localization, scaffolding and activation mechanisms. Generally, TFTK contain an amino terminal plekstrin homology domain (PH domain) involved in lipid interactions and membrane targeting followed by a BTK homology domain (BH) that binds Zn²⁺ and an SH3 domain generally involved in proline rich domain binding. A phosphotyrosine binding SH2 domain and a carboxy terminal ATP binding kinase domain complete the TFTK structure (Mano, et al. (1999) Cytokine Growth Factor Rev. 10, 267-280). TFTK expression is generally limited to hematopoietic lineage cells with the exception of ETK and TEC that are expressed in the liver and endothelial cells, respectively (Smith, et al. (2011) Bioessays 23, 436-446). BMX is expressed in monocytes, granulocytes and cardiac endothelium while BTK is expressed in B cells and mast cells but not plasma cells and T cells. TEC, RLK and ITK are all expressed in T cells. To date the TFTK with the most clear biological role in T cells is ITK.

Antigen/MHC dependent activation of the T cell receptor (TCR) has been shown to transduce its signal through ITK. TCR stimulation results in the activation of the kinase LCK and subsequent phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) on CD3 inducing the binding and activation of the kinase ZAP70. In turn, ZAP70 phosphorylates the adaptor proteins LAT and SLP-76, which together with LCK and other proteins forms a hetermultimeric signaling complex that activates PI3K and generates PIP₃ on the plasma membrane. ITK binds to this signaling complex via SH2 and SH3 domains and to PIP₃ through its PH domain, resulting in LCK dependent phosphorylation of ITK Y511 and subsequent ITK autophosphorylation of Y180. Activated ITK phosphorylates PLCγ1 that, once activated, hydrolyzes PIP₂ to the second messengers IP3 and DAG. The cellular consequences of these sequelae of events include calcium mobilization and flux, PKC and MEK/ERK pathway activation, and transcriptional activation via AP1, NFκactiv NFAT. As a critical enzyme in the TCR activation pathway ITK impacts T cell function in a number of ways including positive and negative selection, cellular differentiation, and cytokine production and release (Takesono, et al. (2002) J. Cell Science 115, 3039-3048; August, et al. (2012) Int. Rev. Immunol. 31, 155-165; Andreotti, et al. (2010) Cold Spring Harb. Perspect. Biol. 2, a002287 1-21).

The role of ITK in T cell function has been delineated through genetic knockdown/kinase inactivation of the ITK gene in rodents and through characterizing human ITK mutant individuals. Mice with a null mutation of the itk gene expressed a decreased number of mature T cells and a block in thymocyte development as well as a decreased TCR driven T cell proliferative response. Interestingly IL2 and CD28 signaling as well as PMA/ionomycin driven responses remained unchanged, suggesting that the ITK response is membrane proximal and stimuli specific (Liao et al. (1995) Immunity 3, 757-769). It appears that ITK is responsible for amplification of TCR signaling versus an ‘on/off’ switch, as dual knockdown of the T cell expressing TFTK, ITK and RLK in mice produce a more complete TCR inactivation phenotype compared with ITK genetic deletion alone (Schaeffer et al. (1999) Science 284, 638-641). In contrast to the modulatory effect that ITK appears to have on naïve T cell activation, it plays a more significant role in T helper cell differentiation. Several studies in ITK deficient mice have demonstrated a reduction in the Th2 protective response to parasitic infection (Fowell et al. (1999) Immunity 11, 399-409; Schaeffer et al. (2001) Nat. Immunol. 2, 1183-1188). This reduced Th2 response was linked to a decrease in concentrations of Th2 cytokines IL4, IL5, IL13 and IL10 (Schaeffer et al. (2001) Nat. Immunol. 2, 1183-1188) and to a reduction in RLK expression. In contrast to the ITK requirement for mounting Th2 driven responses, its impact on Th1 responses is modest. For example, IFNg production in ITK knockout cells is partially inhibited while the double ITK/RLK knockout has a more severe phenotype (Fowell et al. (1999) Immunity 11, 399-409; Schaeffer et al. (2001) Nat. Immunol. 2, 1183-1188; Miller et al. (2004) Immunity 21, 67-80). Evaluation of Th17 T helper cells in ITK knockout in vivo and in vitro studies demonstrated a reduction of IL17A mRNA and protein while having little impact on IL17F (Gomez-Rodriguez et al. (2009) Immunity, 31, 587-597). The role of ITK in cytotoxic CD8+ T cells was investigated using ITK knockout mice. Stimulation of CD8+ T cells deficient in ITK results in a reduction in activation of PLCg1, ERK and p38 MAPK and loss of Ca²⁺ response resulting in decreased proliferative response and effector cytokine production (IL2, IL4 and IFNg) while not impacting cytolytic capacity of these cells (Atherly et al. (2006) J. Immunol. 176, 1571-1581). In addition to the defects observed in CD4+ and CD8+ T cells, natural killer T cell development and TCR stimulated response is reduced in ITK knockout cells and animals (Au-Yueng et al. (2007) J. Immunol. 179, 111-119; Felices et al. (2008) J. Immunol. 180, 3007-3018).

Rodent genetic knockout studies reflect the impact of enzyme expression, not necessarily its catalytic activity, on biological responses. As ITK, through its multiple domain structure, has a role in scaffolding, in addition to its catalytic role. It is important to delineate the impact of blocking each of these functions on cellular biology. Kinase activity-independent ITK activities include recruitment of the guanine nucleotide exchange factor VAV to the cell membrane associated with actin polymerization (PH and SH2 domain dependent) (Atherly et al. (2006) J. Immunol. 176, 1571-1581), antigen receptor stimulation, and receptor activation of SRF (Dombroski et al. (2005) J. Immunol., 174, 1385-1392). However, ITK knockout mice expressing an ITK kinase domain deleted transgene demonstrated that the kinase domain is essential for induction of a normal Th2 response (von Bonin et al. (2011) Exp. Dermatol. 20, 41-47).

The relationship between ITK expression and activity and human disease has recently been documented in studies characterizing individuals exhibiting mutations in the gene encoding this protein and or correlation between expression and disease. The ITK gene was found to be elevated in peripheral blood T cells from patients with moderate to severe atopic dermatitis, a Th2 driven chronic inflammatory skin disease (Hao et al. (2006) FEBS Letts., 580, 2691-2697). An investigation of disease-associated single nucleotide polymorphisms (SNP) in seasonal allergic rhinitis identified ITK as a significant risk factor (Matsumoto et al. (2002) Int. Arch. Allergy Immunol. 129, 327-340). A human primary immunodeficiency was uncovered in siblings that died from immune dysregulation resulting in lymphoproliferation following Epstein Barr Virus (EBV) infection. This disorder was linked to a missense (R335W) mutation in the SH2 domain of ITK resulting in structural instability and reduced steady state levels of the enzyme (Felices et al. (2008) J. Immunol., 180, 3007-3018). The finding was confirmed and extended in studies that identified three patients harboring a C1764G nonsense mutation in ITK resulting in a premature stop codon and reduced expression and/or activity of the protein. These patients presented with EBV-positive Hodgkins Lymphoma (Huck et al. (2009) J. Clin. Invest. 119, 1350-1358). These two reports suggest that mutational disruption of the ITK gene in humans results in an autosomal recessive lymphoproliferative disorder and identifies this kinase as a critical modulator in T cell biology.

In addition to the human genetic data summarized above, animal models support ITK as a therapeutic target for autoimmune and inflammatory disease. ITK knockout mice demonstrate reduced airway hypersensitivity and inflammation in models of allergic asthma (Stepensky et al. (2011) Haematologica, 96, 472-476; Mueller et al. (2003) J. Immunol., 170, 5056-5063; Ferrara et al. (2004) Pulm. Pharmacol. Ther. 17, 301-308). In a murine model of atopic dermatitis, ITK deficient mice do not develop inflammation while ITK inhibition reduces the response in wild type mice (Ferrara et al. (2006) J. Allerg. Clin. Immunol. 117, 780-786). The ITK dependent regulation of TCR dependent Ca²⁺ mobilization and transcription factor induction makes it a critical factor in protecting against Influenza A and HIV infection and viral replication. ITK inhibitors have been shown to alter HIV replication at multiple stages and have the potential as effective HIV therapeutics (Sahu et al. (2008) J. Immunol. 180, 3833-3838).

From an oncology perspective, studies have demonstrated that ITK inhibitors selectively target the killing of acute lymphblastic T-cell leukemia and cutaneous T-cell lymphoma while normal T cells are minimally impacted (Readinger et al. (2008) Proc. Nat. Acad. Sci. USA, 105, 6684-6689). ITK is highly expressed in transformed T-cell lines relative to normal T cells and other cancer cell lines. The impact of ITK inhibition on T cell tumors was confirmed in mouse xenograph models. Cancer evasion of the immune system as a result of tumor antigen tolerance induction versus priming is critical for tumor survival. Tumors that develop a microenvironment that induces T cell unresponsiveness demonstrate altered T cell gene expression suggesting skewing to the Th2 phenotype. ITK inhibition will favor Th1 differentiation and could be used to enhance cancer immunotherapy (Gao et al. (2012) Mol. Pharmacol., 82, 938-947; Horna et al. (2007) Curr. Cancer Drug Targ. 7, 41-53).

Compounds useful as BTK inhibitors for the treatment of inflammation and immune disorders are reported in WO 2012031004 (pub. 8 Mar. 2012). Compounds described therein include arylpyridinones substituted with amino substituents.

Compounds useful as cannabinoid 2-type receptor inhibitors are reported in WO 2002053543 (pub. 11 Jul. 2002). Compounds described therein include arylpyridinones substituted with amido substituents.

Compounds useful as SYK inhibitors for the treatment of inflammation and immune disorders are reported in EP 2489663 (pub. 22 Aug. 2012). Compounds described therein include N-pyrazinyl-indoles and N-pyrazinyl-indole pyridinones substituted with amino substituents.

Compounds useful as thrombin inhibitors for the treatment of blood and coagulation disorders are reported in WO 2000026211 (pub. 11 May 2000). Compounds described therein include N-substituted pyrazinones substituted with amino substituents.

BRIEF SUMMARY

Thus, in various embodiments, the present disclosure provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, of Formula (I):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; X is chosen from N and CR³; m is chosen from 1, 2 and 3; and n is chosen from 0, 1, 2, and 3.

Certain compounds disclosed herein may possess useful ITK inhibiting activity, and may be used in the treatment or prophylaxis of a disease or condition in which ITK plays an active role. Thus, in broad aspect, certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. Certain embodiments provide methods for inhibiting ITK. Other embodiments provide methods for treating an ITK-mediated disorder in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound or composition according to the present disclosure. Also provided is the use of certain compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of ITK.

DETAILED DESCRIPTION Abbreviations and Definitions

To facilitate understanding of the disclosure, a number of terms and abbreviations as used herein are defined below as follows:

When introducing elements of the present disclosure or the preferred embodiment(s) thereof, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.

As used herein, two embodiments are “mutually exclusive” when one is defined to be something which is different than the other. For example, an embodiment wherein R₃ and R₄ combine to form a cycloalkyl is mutually exclusive with an embodiment in which R₃ is ethyl and R₄ is hydrogen. Similarly, an embodiment wherein Y is CH₂ is mutually exclusive with an embodiment wherein Y is NH. However, an embodiment wherein R₃ and R₄ combine to form a cycloalkyl is mutually exclusive with an embodiment in which Y is CH₂.

The term “and/or” when used in a list of two or more items, means that any one of the listed items can be employed by itself or in combination with any one or more of the listed items. For example, the expression “A and/or B” is intended to mean either or both of A and B, i.e. A alone, B alone or A and B in combination. The expression “A, B and/or C” is intended to mean A alone, B alone, C alone, A and B in combination, A and C in combination, B and C in combination or A, B, and C in combination.

When ranges of values are disclosed, and the notation “from n₁ . . . to n₂” or “between n₁ . . . and n₂” is used, where n₁ and n₂ are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 μM (micromolar),” which is intended to include 1 μM, 3 μM, and everything in between to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.).

The term “about,” as used herein, is intended to qualify the numerical values that it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures.

The term “acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon. An “acetyl” group refers to a —C(O)CH₃ group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.

The term “alkenyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon substituent having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(—CH═CH—), (—C::C—)]. Examples of suitable alkenyl substituents include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups.

The term “alkoxy,” as used herein, alone or in combination, refers to an alkyl ether substituent, wherein the term alkyl is as defined below. Examples of suitable alkyl ether substituents include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.

The term “alkyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain alkyl substituent containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, the alkyl will comprise from 1 to 6 carbon atoms. Alkyl groups may be optionally substituted as defined herein. Examples of alkyl substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (—CH₂—). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.

The term “alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino and the like.

The term “alkylidene,” as used herein, alone or in combination, refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.

The term “alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R—S—) substituent wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether substituents include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.

The term “alkynyl,” as used herein, alone or in combination, refers to a straight-chain or branched chain hydrocarbon substituent having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, the alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, the alkynyl comprises from 2 to 4 carbon atoms. The term “alkynylene” refers to a carbon-carbon triple bond attached at two positions such as ethynylene (—C:::C—, —C═C—). Examples of alkynyl substituents include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-1-yl, hexyn-2-yl, and the like. Unless otherwise specified, the term “alkynyl” may include “alkynylene” groups.

The terms “amido” and “carbamoyl” as used herein, alone or in combination, refer to an amino group as described below attached to the parent molecular moiety through a carbonyl group, or vice versa. The term “C-amido” as used herein, alone or in combination, refers to a C(O)N(RR′) group with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R′)— group, with R and R′ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “acylamino” as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an “acylamino” group is acetylamino (CH₃C(O)NH—).

The term “amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R′ may combine to form heterocycloalkyl, either of which may be optionally substituted.

The term “aryl,” as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together. The term “aryl” embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.

The term “arylalkenyl” or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.

The term “arylalkoxy” or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.

The term “arylalkyl” or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.

The term “arylalkynyl” or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.

The term “arylalkanoyl”, “aralkanoyl”, or “aroyl,” as used herein, alone or in combination, refers to an acyl substituent derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, napthoyl, phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.

The term aryloxy as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy.

The terms “benzo” and “benz,” as used herein, alone or in combination, refer to the divalent substituent C₆H₄═ derived from benzene. Examples include benzothiophene and benzimidazole.

The term “carbamate,” as used herein, alone or in combination, refers to an ester of carbamic acid (—NHC(O)O—) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.

The term “O-carbamyl” as used herein, alone or in combination, refers to a —OC(O)NRR′, group-with R and R′ as defined herein.

The term “N-carbamyl” as used herein, alone or in combination, refers to a ROC(O)NR′— group, with R and R′ as defined herein.

The term “carbonyl,” as used herein, when alone includes formyl [—C(O)H] and in combination is a —C(O)— group.

The term “carboxyl” or “carboxy,” as used herein, refers to —C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O— group, where R is as defined herein. A “C-carboxy” group refers to a —C(O)OR groups where R is as defined herein.

The term “cyano,” as used herein, alone or in combination, refers to —CN.

The term “cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein. In certain embodiments, the cycloalkyl will comprise from 5 to 7 carbon atoms. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.

The term “ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms.

The term “ether,” as used herein, alone or in combination, refers to an oxy group bridging two moieties linked at carbon atoms.

The term “halo,” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine.

The term “haloalkoxy,” as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

The term “haloalkyl,” as used herein, alone or in combination, refers to an alkyl substituent having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl substituents. A monohaloalkyl substituent, for one example, may have an iodo, bromo, chloro or fluoro atom within the substituent. Dihalo and polyhaloalkyl substituents may have two or more of the same halo atoms or a combination of different halo substituents. Examples of haloalkyl substituents include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. “Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (—CFH—), difluoromethylene (—CF₂—), chloromethylene (—CHCl—) and the like.

The term “heteroalkyl,” as used herein, alone or in combination, refers to a stable straight or branched chain, or cyclic hydrocarbon substituent, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, —CH₂—NH—OCH₃.

The term “heteroaryl,” as used herein, alone or in combination, refers to a 3 to 15 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom selected from the group consisting of O, S, and N. In certain embodiments, the heteroaryl will comprise from 5 to 7 carbon atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. In addition, the heteroaryl group may contain an oxo group such as the one present in a pyridone group. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.

The terms “heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each the heteroatom may be independently selected from the group consisting of nitrogen, oxygen, and sulfur In certain embodiments, the heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, the heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, the heterocycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, the heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, the heterocycloalkyl will comprise from 5 to 6 ring members in each ring. “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Examples of heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihy-dropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. The heterocycle groups may be optionally substituted unless specifically prohibited.

The term “hydrazinyl” as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., —N—N—.

The term “hydroxy,” as used herein, alone or in combination, refers to —OH.

The term “hydroxyalkyl,” as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

The term “imino,” as used herein, alone or in combination, refers to ═N—.

The term “iminohydroxy,” as used herein, alone or in combination, refers to ═N(OH) and ═N—O—.

The phrase “in the main chain” refers to the longest contiguous or adjacent chain of carbon atoms starting at the point of attachment of a group to the compounds of any one of the formulas disclosed herein.

The term “isocyanato” refers to a —NCO group.

The term “isothiocyanato” refers to a —NCS group.

The phrase “linear chain of atoms” refers to the longest straight chain of atoms independently selected from carbon, nitrogen, oxygen and sulfur.

The term “lower,” as used herein, alone or in a combination, where not otherwise specifically defined, means containing from 1 to and including 6 carbon atoms.

The term “lower aryl,” as used herein, alone or in combination, means phenyl or naphthyl, either of which may be optionally substituted as provided.

The term “lower heteroaryl,” as used herein, alone or in combination, means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four the members may be heteroatoms selected from the group consisting of O, S, and N, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms selected from the group consisting of O, S, and N.

The term “lower cycloalkyl,” as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring members. Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “lower heterocycloalkyl,” as used herein, alone or in combination, means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four may be heteroatoms selected from the group consisting of O, S, and N. Examples of lower heterocycloalkyls include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl. Lower heterocycloalkyls may be unsaturated.

The term “lower amino,” as used herein, alone or in combination, refers to —NRR′, wherein R and R′ are independently chosen from hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted. Additionally, the R and R′ of a lower amino group may combine to form a five- or six-membered heterocycloalkyl, either of which may be optionally substituted.

The term “mercaptyl” as used herein, alone or in combination, refers to an RS— group, where R is as defined herein.

The term “nitro,” as used herein, alone or in combination, refers to —NO₂.

The terms “oxy” or “oxa,” as used herein, alone or in combination, refer to —O—.

The term “oxo,” as used herein, alone or in combination, refers to ═O.

The term “perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.

The term “perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.

The terms “sulfonate,” “sulfonic acid,” and “sulfonic,” as used herein, alone or in combination, refer the —SO₃H group and its anion as the sulfonic acid is used in salt formation.

The term “sulfanyl,” as used herein, alone or in combination, refers to —S—.

The term “sulfinyl,” as used herein, alone or in combination, refers to —S(O)—.

The term “sulfonyl,” as used herein, alone or in combination, refers to —S(O)₂—.

The term “N-sulfonamido” refers to a RS(═O)₂NR′— group with R and R′ as defined herein.

The term “S-sulfonamido” refers to a —S(═O)₂NRR′, group, with R and R′ as defined herein.

The terms “thia” and “thio,” as used herein, alone or in combination, refer to a —S— group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio.

The term “thiol,” as used herein, alone or in combination, refers to an —SH group.

The term “thiocarbonyl,” as used herein, when alone includes thioformyl —C(S)H and in combination is a —C(S)— group.

The term “N-thiocarbamyl” refers to an ROC(S)NR′— group, with R and R′ as defined herein.

The term “O-thiocarbamyl” refers to a —OC(S)NRR′, group with R and R′ as defined herein.

The term “thiocyanato” refers to a —CNS group.

The term “trihalomethanesulfonamido” refers to a X₃CS(O)₂NR— group with X is a halogen and R as defined herein.

The term “trihalomethanesulfonyl” refers to a X₃CS(O)₂— group where X is a halogen.

The term “trihalomethoxy” refers to a X₃CO— group where X is a halogen.

The term “trisubstituted silyl,” as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of substituted amino. Examples include trimethysilyl, tert-butyldimethylsilyl, triphenylsilyl and the like.

Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.

When a group is defined to be “null,” what is meant is that the group is absent.

The term “optionally substituted” means the anteceding group may be substituted or unsubstituted. When substituted, the substituents of an “optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N₃, SH, SCH₃, C(O)CH₃, CO₂CH₃, CO₂H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy. An optionally substituted group may be unsubstituted (e.g., —CH₂CH₃), fully substituted (e.g., —CF₂CF₃), monosubstituted (e.g., —CH₂CH₂F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., —CH₂CF₃). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “optionally substituted with.”

The term R or the term R′, appearing by itself and without a number designation, unless otherwise defined, refers to a moiety selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted. Such R and R′ groups should be understood to be optionally substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R′ and R^(n) where n=(1, 2, 3, . . . n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any variable, substituent, or term (e.g. aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Those of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. Thus, by way of example only, an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.

Asymmetric centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and l-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this disclosure. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms.

The term “bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.

The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

The term “combination therapy” means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

ITK inhibitor is used herein to refer to a compound that exhibits an IC₅₀ with respect to ITK activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the ITK enzyme assay described generally herein below. IC₅₀ is that concentration of inhibitor that reduces the activity of an enzyme (e.g., ITK) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against ITK. In certain embodiments, compounds will exhibit an IC₅₀ with respect to ITK of no more than about 10 μM; in further embodiments, compounds will exhibit an IC₅₀ with respect to ITK of no more than about 5 μM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to ITK of not more than about 1 μM; in yet further embodiments, compounds will exhibit an IC₅₀ with respect to ITK of not more than about 200 nM, as measured in the ITK binding assay described herein.

The phrase “therapeutically effective” is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder or on the effecting of a clinical endpoint.

The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.

As used herein, reference to “treatment” of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen, or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.

The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

The compounds disclosed herein can exist as therapeutically acceptable salts. The present disclosure includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. For a more complete discussion of the preparation and selection of salts, refer to Pharmaceutical Salts: Properties, Selection, and Use (Stahl, P. Heinrich. Wiley-VCHA, Zurich, Switzerland, 2002).

The term “therapeutically acceptable salt,” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.

Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N′-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

A salt of a compound can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.

While it may be possible for the compounds of the subject disclosure to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences. The pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the Condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound of the subject disclosure or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each Containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

Pharmaceutical preparations that can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated to provide slow or Controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally Contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or Continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose Containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose Containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) Condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may Contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In Contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.

Gels for topical or transdermal administration may comprise, generally, a mixture of volatile solvents, nonvolatile solvents, and water. In certain embodiments, the volatile solvent component of the buffered solvent system may include lower (C1-C6) alkyl alcohols, lower alkyl glycols and lower glycol polymers. In further embodiments, the volatile solvent is ethanol. The volatile solvent component is thought to act as a penetration enhancer, while also producing a cooling effect on the skin as it evaporates. The nonvolatile solvent portion of the buffered solvent system is selected from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used. The nonvolatile solvent slows the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system. The amount of this nonvolatile solvent component, as with the volatile solvent, is determined by the pharmaceutical compound or drug being used. When too little of the nonvolatile solvent is in the system, the pharmaceutical compound may crystallize due to evaporation of volatile solvent, while an excess may result in a lack of bioavailability due to poor release of drug from solvent mixture. The buffer component of the buffered solvent system may be selected from any buffer commonly used in the art; in certain embodiments, water is used. A common ratio of ingredients is about 20% of the nonvolatile solvent, about 40% of the volatile solvent, and about 40% water. Several optional ingredients can be added to the topical composition. These include, but are not limited to, chelators and gelling agents. Appropriate gelling agents can include, but are not limited to, semisynthetic cellulose derivatives (such as hydroxypropylmethylcellulose) and synthetic polymers, and cosmetic agents.

Lotions include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface-active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.

Drops may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and, in certain embodiments, including a surface-active agent. The resulting solution may then be clarified by filtration, transferred to a suitable Container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the Container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.

For administration by inhalation, compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds according to the disclosure may take the form of a dry powder composition, for example, a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

Preferred unit dosage formulations are those Containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations described above may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.

Compounds may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units Containing 5 mg to 500 mg, usually around 10 mg to 200 mg.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The compounds can be administered in various modes, e.g. orally, topically, or by injection. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. The specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or Condition being treated. In addition, the route of administration may vary depending on the Condition and its severity.

In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharmaceutically acceptable salt, ester, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if one of the side effects experienced by a patient upon receiving one of the compounds herein is hypertension, then it may be appropriate to administer an anti-hypertensive agent in combination with the initial therapeutic agent. Alternatively, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). Alternatively, by way of example only, the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit. By way of example only, in a treatment for diabetes involving administration of one of the compounds described herein, increased therapeutic benefit may result by also providing the patient with another therapeutic agent for diabetes. In any case, regardless of the disease, disorder or Condition being treated, the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.

Specific, non-limiting examples of possible combination therapies for inflammation include use of certain compounds of the disclosure with: (1) corticosteroids, including but not limited to cortisone, dexamethasone, and methylprednisolone; (2) nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to ibuprofen, naproxen, acetaminophen, aspirin, fenoprofen (NALFON), flurbiprofen (ANSAID), ketoprofen, oxaprozin (DAYPRO), diclofenac sodium (VOLTAREN), diclofenac potassium (CATAFLAM), etodolac (LODINE), indomethacin (INDOCIN), ketorolac (TORADOL), sulindac (CLINORIL), tolmetin (TOLECTIN), meclofenamate (MECLOMEN), mefenamic acid (PONSTEL), nabumetone (RELAFEN) and piroxicam (FELDENE); (3) immunosuppressants, including but not limited to methotrexate (RHEUMATREX), leflunomide (ARAVA), azathioprine (IMURAN), cyclosporine (NEORAL, SANDIMMUNE), tacrolimus and cyclophosphamide (CYTOXAN); (4) CD20 blockers, including but not limited to rituximab (RITUXAN); (5) Tumor Necrosis Factor (TNF) blockers, including but not limited to etanercept (ENBREL), infliximab (REMICADE) and adalimumab (HUMIRA); (6) interleukin-1 receptor antagonists, including but not limited to anakinra (KINERET); (7) interleukin-6 inhibitors, including but not limited to tocilizumab (ACTEMRA); (8) interleukin-17 inhibitors, including but not limited to AIN457; (9) Janus kinase inhibitors, including but not limited to tasocitinib; and (10) syk inhibitors, including but not limited to fostamatinib.

Specific, non-limiting examples of possible combination therapies for the treatment of cancer include use of certain compounds of the disclosure with: (1) alkylating agents, including but not limited to cisplatin (PLATIN), carboplatin (PARAPLATIN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), busulfan (MYLERAN) and cyclophosphamide (ENDOXAN); (2) anti-metabolites, including but not limited to mercaptopurine (PURINETHOL), thioguanine, pentostatin (NIPENT), cytosine arabinoside (ARA-C), gemcitabine (GEMZAR), fluorouracil (CARAC), leucovorin (FUSILEV) and methotrexate (RHEUMATREX); (3) plant alkaloids and terpenoids, including but not limited to vincristine (ONCOVIN), vinblastine and paclitaxel (TAXOL); (4) topoisomerase inhibitors, including but not limited to irinotecan (CAMPTOSAR), topotecan (HYCAMTIN) and etoposide (EPOSIN); (5) cytotoxic antibiotics, including but not limited to actinomycin D (COSMEGEN), doxorubicin (ADRIAMYCIN), bleomycin (BLENOXANE) and mitomycin (MITOSOL); (6) angiogenesis inhibitors, including but not limited to sunitinib (SUTENT) and bevacizumab (AVASTIN); and (7) tyrosine kinase inhibitors, including but not limited to imatinib (GLEEVEC), erlotinib (TARCEVA), lapatininb (TYKERB) and axitinib (INLYTA).

In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.

Thus, in another aspect, certain embodiments provide methods for treating ITK-mediated disorders in a human or animal subject in need of such treatment comprising administering to the subject an amount of a compound disclosed herein effective to reduce or prevent the disorder in the subject, in combination with at least one additional agent for the treatment of the disorder that is known in the art. In a related aspect, certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of ITK mediated disorders.

Specific diseases to be treated by the compounds, compositions, and methods disclosed herein include autoimmune disorders, chronic inflammatory disorders, auto-inflammatory disorders, pain, inflammatory disorders, allergic disorders, autoimmune disorders and the like.

In some embodiments, the methods described herein are used to treat a patient in need thereof suffering from inflammatory disorders, allergic disorders, and autoimmune disorders. Examples of disorders include, but are not limited to asthma, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Contact hypersensitivity and inflammatory bowel disease.

Diseases to be treated by the compounds, compositions, and methods disclosed herein related to cancer include cancer specific to T-cells such as T-cell lymphoma and lymphblastic T-cell leukemia.

Diseases to be treated by the compounds, compositions, and methods disclosed herein include HIV.

Besides being useful for human treatment, certain compounds and formulations disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

Compounds

The present disclosure provides a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, of Formula (I):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl where aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; X is chosen from N and CR³; m is chosen from 1, 2 and 3; and n is chosen from 0, 1, 2, and 3.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; X is chosen from N or CR³; m is chosen from 1, and 2; and n is chosen from 0, 1, and 2.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; X is CR³; m is 1; and n is chosen from 0, 1, and 2.

In some embodiments, the compound is composed of formula (II):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; X is chosen from N and CR³; and m is chosen from 1, 2 and 3.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; X is chosen from N and CR³; m is chosen from 1 and 2.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; X is CR³; and m is 1.

In some embodiments, the compound is composed of formula (III):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; m is chosen from 1, 2 and 3.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; m is chosen from 1 and 2.

In certain embodiments, Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; m is 1.

In particular embodiments, the compound is selected from the group consisting of: 5-((1-(2-chloroacetyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; (E)-5-((1-(but-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-2′-methyl-[3,4′-bipyridin]-6(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(6-methoxypyrazin-2-yl)pyridin-2(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(2-(methylamino)pyrimidin-4-yl)pyridin-2(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(6-(methylamino)pyrazin-2-yl)pyridin-2(1H)-one; (E)-N-methyl-4-oxo-4-(3-((6-oxo-1,6-dihydro-[3,4′-bipyridin]-5-yl)amino)azetidin-1-yl)but-2-enamide; and (E)-5-((1-(4-(methylamino)but-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one.

In certain embodiments, Ar is phenyl, 3-methoxyphenyl, 3-aminomethylphenyl, 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is independently chosen from hydrogen, halo or C₁₋₄ alkyl; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and 3.

In certain embodiments, Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is independently chosen from hydrogen, halo or C₁₋₄ alkyl; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and 3.

In certain embodiments, Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and 3.

In certain embodiments, Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1 and 2.

In certain embodiments, Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C1-4 alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1 and 2.

Also provided are embodiments wherein any of embodiment above in paragraphs [0141]-[0157] above may be combined with any one or more of these embodiments, provided the combination is not mutually exclusive.”

Methods of Treatment

The present disclosure provides compounds and pharmaceutical compositions that inhibit kinase activity, particularly ITK activity and are thus useful in the treatment or prevention of disorders associated with ITK. Compounds and pharmaceutical compositions of the present disclosure selectively inhibit ITK and are thus useful in the treatment or prevention of a range of disorders associated with the activation of ITK which includes, but are not limited to respiratory diseases, allergic diseases, autoimmune diseases, inflammatory disorders, immunological disorders, proliferative disorders, transplant rejection, graft versus host disease, HIV, aplastic anemia, pain including inflammatory pain and other diseases and disorders associated with ITK.

In particular, the compounds of the present disclosure may be used to prevent or treat asthma, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Contact hypersensitivity and inflammatory bowel disease.

The compounds of the present disclosure may be used to prevent or treat T-cell lymphoma and lymphblastic T-cell leukemia.

The compounds of the present disclosure may be used to prevent or treat HIV.

Compounds and pharmaceutically acceptable compositions of the present disclosure can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions may have potential utility in combination with other therapies for the treatment of immune, inflammatory, proliferative, and allergic disorders. Example includes but not limited to co-administration with steroids, leukotriene antagonists, anti-histamines, anti-cancer agents, protein kinase inhibitors, cyclosporine, or rapamycin.

The compounds of the present disclosure may be used to prevent or treat an ITK-mediated disorder by the sequential or co-administration of another therapeutic agent.

In certain embodiments, the therapeutic agent is selected from taxanes, inhibitors of bcr-abl, inhibitors of EGFR, DNA damaging agents, and antimetabolites.

In particular embodiments, the therapeutic agent is selected from Paclitaxel, Gleevec, dasatinib, nilotinib, Tarceva, Iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU.

In particular embodiments, the therapeutic agent is selected from camptothecin, doxorubicin, idarubicin, Cisplatin, taxol, taxotere, vincristine, tarceva, a MEK inhibitor, U0126, a KSP inhibitor, vorinostat, Gleevec, dasatinib, and nilotinib.

Compounds and pharmaceutical compositions of the present disclosure selectively inhibit ITK and are thus useful in the treatment or prevention of a range of disorders associated with the activation of ITK which includes, but are not limited to chronic obstructive pulmonary disease (COPD) such as irreversible COPD; asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (for example, late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia; sinusitis, chronic rhinosinusitis, nasosinusal polyposis; pulmonary fibrosis; inflammatory bowel disease; Guillain-Barre syndrome, acute or chronic inflammation, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis; psoriasis, atopic dermatitis, Contact dermatitis and other eczematous dermitides, sebonhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythema, cutaneous eosinophilias, uveitis, Alopecia greata and vernal conjunctivitis; Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, food-related allergies which have effects remote from the gut, for example, migraine, rhinitis and eczema; multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, type II diabetes, nephritic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome and idiopathic thrombocytopenia pupura; tuberculosis; organ and bone marrow transplant rejection; graft-versus-host disease.

The compounds of the present disclosure are useful for the treatment of cancer such as, but are not limited to breast cancer, skin cancer, bone cancer, prostate cancer, liver cancer, lung cancer, non-small cell lung cancer, brain cancer, cancer of the larynx, gall bladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, colon, stomach, bronchi, and kidney cancer, basal cell carcinoma, squamous cell carcinoma, metastatic skin carcinoma, osteo sarcoma, Ewing's sarcoma, myeloma, giant cell tumor, small-cell lung tumor, islet cell tumor, primary brain tumor, lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuromas, intestinal ganglioneuromas, ovarian tumor, cervical dysplasia, neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic sarcoma, malignant hypercalcemia, renal cell tumor, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.

General Synthetic Methods for Preparing Compounds

Compounds of the present disclosure can be prepared using methods illustrated in general synthetic schemes and experimental procedures detailed below. General synthetic schemes and experimental procedures are presented for purposes of illustration and are not intended to be limiting. Starting materials used to prepare compounds of the present disclosure are commercially available or can be prepared using routine methods known in the art. Representative procedures for the preparation of compounds of the disclosure are outlined in Schemes 1-3 below. Solvents and reagents, whose synthetic preparations are not described below, can be purchased at Sigma-Aldrich or Fisher Scientific.

The desired pyridinone analogs may be prepared as outlined in Scheme 1. Reaction of 1a with methyl iodide using silver carbonate as a base in benzene provides methoxypyridine 1b. Bromination of 1b using bromine in a sodium acetate/acetic mixture furnishes 1c. Following standard coupling Conditions 1c is reacted with the desired amine using a palladium catalyst such as Pd₂dba₃ with X-phos as the ligand and cesium carbonate as a weak base in dioxane to provide 1d. Utilizing standard Suzuki coupling Conditions 1d is reacted with the desired boronic acid using a palladium catalyst such as Pd(dppf)Cl₂ with a weak base such as K₃PO₄ in dioxane that provides 1e. The removal of the protecting group and formation of the desired pyridinone takes place by treating 1e with ethanolic HCl to give 1f. This compound is treated with the desired halide in the presence of triethylamine in dichloromethane to give 1 g where R⁴ contains a suitable electrophile.

The synthesis of N-methylpyridinones is shown in Scheme 2. Reaction of 1e with sodium hydride in a solvent such as THF or DMF followed by treatment with methyl iodide furnishes 2a. The removal of the protecting group and formation of the desired pyridinone takes place by treating 2a with ethanolic HCl to give 2b. This compound is treated with the desired halide in the presence of triethylamine in dichloromethane to give 2c where R⁴ contains a suitable electrophile.

A number of boronic acids may be used in the preparation of the desired analogs as shown in Scheme 3. Utilizing standard Suzuki coupling Conditions 1d is reacted with the desired boronic acid using a palladium catalyst such as Pd(dppf)Cl₂ with a weak base such as K₃PO₄ in dioxane that provides 3a. The removal of the protecting group and formation of the desired pyridinone takes place by treating 3a with ethanolic HCl to give 3b. This compound is treated with the desired halide in the presence of triethylamine in dichloromethane to give 3c where R⁴ contains a suitable electrophile.

The synthesis of pyridinones with aryl amide groups is shown in Scheme 5. Protection of 5a as a benzyl carbamate provides 5b. Iodination of 5b using NIS followed by reaction with iodomethane in the presence of silver carbonate provides 5c. The appropriate boronate ester was formed by treating 5c with bis(pinacolate)diboron in the presence of a palladium catalyst to give 5d. The desired coupling partner, 5g, was formed by reaction of acid 5f with amine 5e under standard HATU amide coupling conditions. Suzuki-based coupling of 5d and 5g was carried out in the presence a palladium catalyst such as Pd(PPh3)4 and a base such as potassium carbonate to give bis-aryl 5h. Deprotection of the methoxy group and concomitant formation of the pyridinone was carried out by treating 5h with trimethylsilyl chloride in the presence of sodium iodide to give pyridinone 5i. Hydrogenation of 5i using Pearlmans catalyst in methanol gives deprotected 5j. Condensation of amino 5j with the desired heterocyclic ketone using sodium cyanoborohydride and zinc chloride as a catalyst provides the desired carbamate analog, which was deprotected using hydrochloric acid in ethanol to give 5k. The amide coupling was accomplished by treating amine 5k with the desired carboxylic acid under HATU or related amide coupling conditions to provide 5l.

The disclosure is further illustrated by the following examples.

Example 1 (R)-5-((1-(2-Chloroacetyl)piperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Step 1: 5-Bromo-2-methoxypyridine

Silver carbonate (16.0 g, 57.8 mmol) and methyl iodide (6.5 mL, 103 mmol) were sequentially added to a solution of 5-bromopyridin-2(1H)-one (15.0 g, 86.2 mmol) in benzene (225 mL). The mixture was stirred for 16 h at 50° C. After cooling to room temperature, the mixture was filtered through celite and concentrated. Purification by chromatography using 1-5% ethyl acetate in pet ether provided 12 g of the desired compound: ¹H NMR (300 MHz, CDCl₃) 8.15-8.25 (narrow m, 1H), 7.63 (dd, J=9, 3 Hz, 1H), 6.63 (d, J=9 Hz, 1H), 3.92 (s, 3H).

Step 2: 3,5-Dibromo-2-methoxypyridine

Bromine (17.8 g, 111 mmol) was added to a solution of 5-bromo-2-methoxypyridine (12.0 g, 63.8 mmol), sodium acetate (5.23 g, 63.8 mmol), and acetic acid (65 mL). The mixture was stirred at 80° C. for 4 h and then at room temperature for 12 h. The mixture was diluted with ether and washed with water, sodium bicarbonate and hypo solution. The organic layer was dried over sodium sulphate, filtered and concentrated. Purification by chromatography using 1-5% ethyl acetate in pet ether provided 10.6 g of the desired compound: ¹H NMR (300 MHz, DMSO-d₆) 8.20-8.40 (m, 2H), 3.92 (s, 3H).

Step 3: (R)-tert-Butyl 3-((5-bromo-2-methoxypyridin-3-yl)amino)piperidine-1-carboxylate

(R)-tert-Butyl 3-aminopiperidine-1-carboxylate (2.99 g, 15.0 mmol) and cesium carbonate (9.84 g, 30.0 mmol) were added to a solution of 3,5-dibromo-2-methoxypyridine (4.00 g, 15.0 mmol) in dioxane (100 mL). The mixture was degassed for 20 min and then Xphos (0.692 g, 1.20 mmol) and Pd₂(dba)₃ (1.10 g, 1.20 mmol) were added. The mixture was stirred at 110° C. for 12 h. The mixture was allowed to cool to room temperature and was filtered through celite and concentrated. The residue was purified by chromatography using 5-10% ethyl acetate in pet ether to give 2 g of the desired compound: ¹H NMR (300 MHz, DMSO-d₆) 7.44 (narrow m, 1H), 6.95 (s, 1H), 5.15-5.20 (m, 1H), 3.91 (s, 3H), 3.50-3.95 (m, 2H), 3.20-3.40 (m, 1H), 2.80-3.05 (m, 2H), 1.80-1.95 (m, 1H), 1.10-1.70 (m, 3H), 1.36 (s, 9H); MS (ES) m/z 386, 384 (M+).

Step 4: (R)-tert-Butyl 3-((6-methoxy-[3,4′-bipyridin]-5-yl)amino)piperidine-1-carboxylate

Pyridine-4-boronic acid (0.950 g, 7.77 mmol) and potassium phosphate (2 M, 70 mL) was added to a solution of (R)-tert-butyl 3-((5-bromo-2-methoxypyridin-3-yl)amino)piperidine-1-carboxylate (2.00 g, 5.18 mmol) in dioxane (70 mL). The mixture was degassed for 20 min and then Pd(dppf)Cl₂ (1.28 g, 1.55 mmol) was added. The mixture was stirred at 80° C. for 6 h. The mixture was allowed to cool to room temperature and was filtered through celite and concentrated. The residue was purified by chromatography using 40-50% ethyl acetate in pet ether to give 1 g of the desired compound: ¹H NMR (300 MHz, DMSO-d₆) 8.55-8.65 (narrow m, 2H), 7.85 (s, 1H), 7.65-7.75 (narrow m, 2H), 7.10-7.30 (m, 1H), 5.03 (br s, 1H), 3.94 (s, 3H), 3.45-3.80 (m, 3H), 2.90-3.15 (m, 2H), 1.85-2.00 (m, 1H), 1.15-1.75 (m, 12H); MS (ES) m/z 385 (M+H).

Step 5: (R)-5-(Piperidin-3-ylamino)-[3,4′-bipyridin]-6(1H)-one hydrochloride

A solution of HCl in dioxane (20 mL) was added to (R)-tert-butyl 3-((6-methoxy-[3,4′-bipyridin]-5-yl)amino)piperidine-1-carboxylate (1.00 g, 2.60 mmol) in ethanol (10 mL). The mixture was heated at 80° C. for 12 h in a sealed tube. After cooling to room temperature the mixture was concentrated and the crude residue was triturated with diethyl ether to afford 0.60 g of the desired compound: ¹H NMR (300 MHz, DMSO-d₆) 12.29 (br s, 1H), 9.30-9.50 (m, 1H), 8.90-9.10 (m, 1H), 8.76 (br s 2H), 8.32 (br s, 2H), 7.74 (s, 1H), 7.04 (s, 1H), 5.65-5.90 (m, 1H), 3.20-4.10 (m, 5H), 2.60-2.90 (m, 1H), 1.60-2.05 (m, 3H); MS (ES) m/z 271 (M+H).

Step 6: (R)-5-((1-(2-Chloroacetyl)piperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Chloroacetyl chloride (0.021 mL, 0.26 mmol) was added to a solution of (R)-5-(piperidin-3-ylamino)-[3,4′-bipyridin]-6(1H)-one hydrochloride (100 mg, 0.26 mmol) and triethylamine (0.17 mL, 1.2 mmol) in dichloromethane (5.0 mL) at 0° C. The solution was stirred at 0° C. for 30 min and was concentrated. The residue was diluted with water and extracted with 5% methanol in ethyl acetate. The organic layer was dried over sodium sulphate, filtered, and concentrated. The residue was purified on silica gel eluting with 10% methanol in dichloromethane to provide 20 mg of the title compound: ¹H NMR (300 MHz, DMSO-d₆) 11.80-11.95 (m, 1H), 8.45-8.60 (m, 2H), 7.60-7.70 (m, 2H), 7.20-7.35 (m, 1H), 6.70-6.95 (m, 1H), 5.50-5.80 (m, 1H), 4.20-4.50 m, 1H), 3.45-3.95 (m, 1H), 2.95-3.40 (m, 2H), 2.65-2.90 (m, 1H), 1.35-2.15 (m, 2H); MS (ES) m/z 347 (M+H).

Example 2 (R)-5-((1-Acryloylpiperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 1, reaction of (R)-5-(piperidin-3-ylamino)-[3,4′-bipyridin]-6(1H)-one hydrochloride (Example 1 Step 5) with acroyl chloride provided the desired compound after purification: ¹H NMR (300 MHz, DMSO-d₆) 11.83 (s, 1H), 8.53 (d, J=9 Hz, 2H), 7.55-7.70 (m, 1H), 7.20-7.30 (m, 1H), 6.65-6.90 (m, 2H), 6.00-6.20 (m, 1H), 5.55-5.75 (m, 1H), 5.20-5.40 (m, 1H), 3.80-4.05 (m, 1H), 2.95-45 (4H), 1.90-2.05 (m, 1H), 1.40-1.80 (m, 2H), 1.10-1.35 (m, 1H); MS (ES) m/z 325 (M+H).

Example 3 (R)-5-((1-Acryloylpyrrolidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 1, but using (R)-tert-butyl 3-aminopyrrolidine-1-carboxylate (Example 1 Step 3) and reaction with acroyl chloride (Example 1 Step 6) provided the desired compound after purification: ¹H NMR (300 MHz, DMSO-d₆) 11.86 (br s, 1H), 8.52, (d, J=4.8 Hz, 2H), 7.64 (br s 2H), 7.28 (br s, 1H), 6.75 (d, J=7.2 Hz, 1H), 6.50-6.70 (m, 1H), 6.13 (d, J=16.8 Hz, 1H), 6.55-6.75 (m, 2H), 4.10-4.30 (m, 1H), 3.90-4.05 (m, 1H), 3.20-3.65 (m, 3H), 1.85-2.35 (m, 2H); MS (ES) m/z 311 (M+H).

Example 4 5-((1-(2-Chloroacetyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 1, but using tert-butyl 3-aminoazetidine-1-carboxylate (Example 1 Step 3) and reaction with chloroacetyl chloride (Example 1 Step 6) provided the desired compound after purification: ¹H NMR (300 MHz, DMSO-d₆) 11.87 (br s, 1H), 8.52 (d, J=5.4 Hz, 2H), 7.61 (d, J=6.0 Hz, 2H), 7.25-7.40 (m, 1H), 6.45-6.55 (m, 1H), 6.27 (d, J=6.3 Hz, 1H), 4.86 (apparent t, J=7.7 Hz, 1H), 4.25-4.44 (m, 2H), 4.13 (narrow m, 2H), 4.00-4.25 (m, 1H), 3.85-4.00 (m, 1H); MS (ES) m/z 319 (M+H).

Example 5 5-((1-Acryloylazetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 1, but using tert-butyl 3-aminoazetidine-1-carboxylate (Example 1 Step 3) and reaction with acroyl chloride (Example 1 Step 6) provided the desired compound after purification: ¹H NMR (300 MHz, DMSO-d₆) 11.86 (br s, 1H), 8.52 (d, J=6.3 Hz, 2H), 7.62 (dd, J=4.2, 1.5 Hz, 2H), 7.25-7.35 (m, 1H), 6.61 (d, J=2.1 Hz, 1H), 6.20-6.40 (m, 2H), 6.10 (dd, J=17.1, 2.4 Hz, 1H), 5.67 (dd, J=10.2, 2.1 Hz, 1H), 4.61 (apparent t, J=7.8 Hz, 1H), 4.25-4.45 (m, 2H), 4.05-4.15 (m, 1H), 3.80-3.95 (m, 1H); MS (ES) m/z 297 (M+H).

Example 6 (E)-5-((1-(But-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 1, but using tert-butyl 3-aminoazetidine-1-carboxylate (Example 1 Step 3) and reaction with (E)-but-2-enoyl chloride (Example 1 Step 6) provided the desired compound after purification: ¹H NMR (300 MHz, DMSO-d₆) 11.83 (br s, 1H), 8.52 (d, J=5.7 Hz, 2H), 7.61 (d, J=5.7 Hz, 2H), 7.25-7.35 (m, 1H), 6.55-6.75 (m, 1H), 6.49 (d, J=2.1 Hz, 1H), 6.26 (d, J=6.6 Hz, 1H), 6.01 (dd, J=15.2, 1.7 Hz, 1H), 4.45-4.65 (m, 1H), 4.20-4.40 (m, 2H), 4.07 (dd, J=8.6, 4.7 Hz, 1H), 3.87 (dd, J=9.9, 4.8 Hz, 1H), 1.82 (dd, J=6.6, 1.5 Hz, 3H); MS (ES) m/z 311 (M+H).

Example 14 (E)-5-((1-Cinnamoylazetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one

Step 1: tert-Butyl 3-((5-chloro-2-methoxypyridin-3-yl)amino)azetidine-1-carboxylate

To a solution of 3-bromo-5-chloro-2-methoxypyridine (5.00 g, 33.7 mmol) in toluene (100 mL) was added tert-butyl 3-aminoazetidine-1-carboxylate (5.8 g, 18.5 mmol), Xantphos (650 mg, 1.12 mmol), Cs₂CO₃ (14.6 g, 44.9 mmol) and Pd₂(dba)₃ (514 mg, 0.562 mmol). The reaction mixture was stirred at 60° C. under nitrogen for 4 days. After cooling to RT, the reaction mixture was filtered, washed with ethyl acetate (100 mL), the organic layer washed with water (60 mL), brine (60 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (ethyl acetate/hexane) to obtain 5.6 g of tert-butyl 3-((5-chloro-2-methoxypyridin-3-yl)amino)azetidine-1-carboxylate as a white-yellow oil (80%): ¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, J=2.2 Hz, 1H), 6.36 (d, J=2.2 Hz, 1H), 4.52 (d, J=6.5 Hz, 1H), 4.24 (dd, J=8.9, 7.1 Hz, 2H), 4.05 (m, 1H), 3.89 (s, 3H), 3.70 (dd, J=9.1, 4.8 Hz, 2H), 1.37 (s, 9H); MS (ES) m/z 314 (M+H).

Step 2: tert-Butyl 3-((2′-fluoro-6-methoxy-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate

To a solution of tert-butyl 3-((5-chloro-2-methoxypyridin-3-yl)amino)azetidine-1-carboxylate (2.00 g, 6.37 mmol) in dioxane/water (5:1, 38 mL) was added 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.85 g 8.29 mmol), Xphos-Pd-G2 (125 mg, 0.159 mmol), and K₃PO₄ (2.90 g, 13.7 mmol). The reaction mixture was stirred at 100° C. under nitrogen for 1 h. After cooling to RT, the reaction mixture was filtered and washed with ethyl acetate (100 mL). The organic layer was washed with water (60 mL), brine (60 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to obtain 2.4 g of tert-butyl 3-((2′-fluoro-6-methoxy-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate as a white yellow solid (100%): ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, J=5.3 Hz, 1H), 7.75 (d, J=2.2 Hz, 1H), 7.24 (dt, J=5.5, 1.6 Hz, 1H), 6.96 (t, J=1.5 Hz, 1H), 6.58 (d, J=2.1 Hz, 1H), 4.60 (d, J=6.5 Hz, 1H), 4.29 (dd, J=8.9, 7.1 Hz, 2H), 4.19 (qd, J=6.7, 5.7, 1.9 Hz, 1H), 3.99 (s, 3H), 3.75 (dd, J=9.1, 4.7 Hz, 2H), 1.38 (s, 9H); MS (ES) m/z 375 (M+H).

Step 3: tert-Butyl 3-((6-methoxy-2′-(methylamino)-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate

To a solution of tert-butyl 3-((2′-fluoro-6-methoxy-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate (530 mg, 1.42 mmol) in NMP (3 mL) was added CH₃NH₂/MeOH (5 mL). The reaction mixture was stirred while being heated at 140° C. in a microwave for 1 h. The mixture was cooled to rt, the solvent was removed and diluted with ethyl acetate (100 mL). The organic layer was washed with water (60 mL), brine (60 mL), dried over Na₂SO₄, filtered, concentrated in vacuo, and the residue was purified by flash chromatography to obtain 436 mg of tert-butyl 3-((6-methoxy-2′-(methylamino)-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate as a yellow solid (80%): ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J=5.3 Hz, 1H), 7.72 (d, J=2.1 Hz, 1H), 6.63 (dd, J=5.3, 1.5 Hz, 1H), 6.58 (s, 1H), 6.39 (d, J=1.7 Hz, 1H), 4.63 (d, J=6.7 Hz, 1H), 4.53 (d, J=6.5 Hz, 1H), 4.27 (dd, J=8.8, 7.1 Hz, 2H), 4.18 (ddt, J=9.4, 7.0, 3.4 Hz, 1H), 3.97 (s, 3H), 3.74 (dd, J=9.0, 4.6 Hz, 2H), 2.90 (d, J=4.2 Hz, 3H), 1.37 (s, 9H); MS (ES) m/z 386 (M+H).

Step 4: 5-(Azetidin-3-ylamino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one di-hydrobromide

A solution of tert-butyl 3-((6-methoxy-2′-(methylamino)-[3,4′-bipyridin]-5-yl)amino)azetidine-1-carboxylate (890 mg, 2.31 mmol) in 40% HBr (9 mL) was stirred at 50° C. for 14 h. After the mixture was cooled to RT, 9 mL of methanol was added, the residue filtered, washed with ethyl acetate (5 mL), and dried in vacuo to afford 5-(azetidin-3-ylamino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one di-hydrobromide (947 mg, 89%) as yellow solid: ¹H NMR (400 MHz, DMSO-d₆) δ 12.97 (s, 1H), 12.18 (d, J=5.9 Hz, 1H), 8.87 (s, 1H), 8.68 (s, 1H), 8.50 (s, 1H), 7.89 (d, J=6.8 Hz, 1H), 7.52 (dd, J=5.8, 2.6 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J=7.0, 1.8 Hz, 1H), 6.60 (s, 1H), 6.50 (d, J=2.5 Hz, 1H), 4.48 (d, J=8.9 Hz, 1H), 4.34 (m, 2H), 4.09-3.97 (m, 2H), 2.99 (d, J=4.8 Hz, 3H); MS (ES) m/z 272 (M+H).

Step 5: (E)-5-((1-Cinnamoylazetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one

A solution of 5-(azetidin-3-ylamino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one di-hydrobromide (80.0 mg, 0.185 mmol) in DMF (1 mL) was added cinnamic acid (60 mg, 0.41 mmol), HATU (105 mg, 0.277 mmol), and DIPEA (120 mg, 0.924 mmol). The reaction mixture was stirred at RT under nitrogen for 16 h. The residue was purified by Prep HPLC (ethyl acetate/hexane) to afford (E)-5-((1-cinnamoylazetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one (41 mg, 55%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 11.25 (s, 1H), 8.11 (d, J=5.4 Hz, 1H), 7.69 (d, J=15.6 Hz, 1H), 7.52 (dd, J=6.7, 3.0 Hz, 2H), 7.37 (dd, J=5.0, 2.0 Hz, 3H), 7.09 (d, J=2.2 Hz, 1H), 6.63 (dd, J=5.4, 1.6 Hz, 1H), 6.48 (d, J=15.6 Hz, 1H), 6.38 (d, J=1.9 Hz, 2H), 5.48 (d, J=6.6 Hz, 1H), 4.80-4.65 (m, 2H), 4.63-4.50 (m, 1H), 4.46-4.32 (m, 1H), 4.26-4.05 (m, 2H), 2.98 (d, J=4.8 Hz, 3H); MS (ES) m/z 402 (M+H).

Example 15 (E)-2′-(Methylamino)-5-((1-(4-phenylbut-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 14 but substituting (E)-4-phenylbut-2-enoic acid for cinnamic acid in Step 5 afforded (E)-2′-(methylamino)-5-((1-(4-phenylbut-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one in 47% yield: ¹H NMR (400 MHz, CDCl₃) δ 11.68 (s, 1H), 8.10 (d, J=5.3 Hz, 1H), 7.39-7.33 (m, 2H), 7.30 (dd, J=8.5, 6.7 Hz, 2H), 7.25-7.19 (m, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.61 (dd, J=5.3, 1.5 Hz, 1H), 6.48 (d, J=15.9 Hz, 1H), 6.36 (d, J=1.9 Hz, 2H), 6.29 (dt, J=15.9, 6.9 Hz, 1H), 5.48 (d, J=6.7 Hz, 1H), 4.75 (d, J=5.6 Hz, 1H), 4.60 (t, J=7.9 Hz, 1H), 4.47 (dd, J=10.2, 7.4 Hz, 1H), 4.37-4.28 (m, 1H), 4.10 (dd, J=8.7, 4.7 Hz, 1H), 4.02 (dd, J=10.3, 4.9 Hz, 1H), 3.11 (dd, J=6.8, 1.5 Hz, 2H), 2.96 (d, J=4.8 Hz, 3H); MS (ES) m/z 416 (M+H).

Example 16 5-((1-Acryloylazetidin-3-yl)amino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride

Step 1: Benzyl (2-hydroxypyridin-3-yl)carbamate

To a solution of 3-aminopyridin-2-ol (8.05 g, 73.0 mmol) in DCM (20 mL) was added CbzCl (13.2 mL, 93.0 mmol) and Na₂CO₃ (18.0 g, 170 mmol). The mixture was stirred at room temperature overnight. Ethyl acetate (500 mL) was added and the mixture was washed with NaHCO₃ (50 mL). The organic phase was dried over MgSO₄, filtered and concentrated. The crude product was purified by combi-flash (ISCO, 40 g silica, MeOH/DCM from 3% to 5%, UV254) to afford benzyl (2-hydroxypyridin-3-yl)carbamate (16.2 g, 90% yield): MS (ES) m/z 245 (M+H).

Step 2: Benzyl (2-hydroxy-5-iodopyridin-3-yl)carbamate

To a solution of benzyl (2-hydroxypyridin-3-yl)carbamate (16.1 g, 65.9 mmol) in DCM (500 mL) was added NIS (17.8 g, 79.1 mmol) and the mixture heated at reflux overnight. After cooling, the mixture was filtered to afford benzyl (2-hydroxy-5-iodopyridin-3-yl)carbamate (16 g, 65% yield) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.27 (s, 1H), 7.72 (s, 1H), 7.29-7.40 (m, 5H), 5.21 (s, 2H); MS (ES) m/z 370 (M+H).

Step 3: Benzyl (5-iodo-2-methoxypyridin-3-yl)carbamate

To a solution of benzyl (2-hydroxy-5-iodopyridin-3-yl)carbamate (16 g, 43 mmol) in CHCl₃ (250 mL) was added Ag₂CO₃ (16.1 g, 58.4 g) and methyl iodide (27.0 mL, 434 mmol) in the dark, and the mixture stirred at RT for overnight. The solid was removed by filtration and the solvent was concentrated and purified by combi-flash (ISCO, 40 g silica, UV254, 5:1 pet ether/ethyl acetate) to afford benzyl (5-iodo-2-methoxypyridin-3-yl)carbamate (8.85 g, 53% yield) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.61 (br, 1H), 7.98 (d, J=1.6 Hz, 1H), 7.35-7.42 (m, 5H), 7.12 (s, 1H), 5.21 (s, 2H), 3.95 (s, 3H); MS (ES) m/z 385 (M+H).

Step 4: Benzyl (2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)carbamate

To a solution of benzyl (5-iodo-2-methoxypyridin-3-yl)carbamate (8.85 g, 23.1 mmol) in 1,4-dioxane (200 mL) was added bis(pinacolate)diboron (6.12 g, 24.2 mmol), PdCl₂(PPh₃)₂ (0.49 g, 0.70 mmol), KOAc (6.8 g, 69 mmol) and the mixture was stirred at reflux under nitrogen overnight. After cooling to room temperature and evaporation the solvent, the residue was purified by combi-flash (ISCO, 40 g silica, UV254, 3:1 pet ether/ethyl acetate) to afford benzyl (2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)carbamate (8.13 g, 92% yield) as a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 8.61 (s, 1H), 8.19 (d, J=1.6 Hz, 1H), 7.34-7.43 (m, 5H), 7.14 (s, 1H), 5.22 (s, 2H), 3.99 (s, 3H), 1.32 (s, 12H); MS (ES) m/z 385 (M+H).

Step 5: 4-Bromo-N-(4-isopropyl-3-methylphenyl)picolinamide

To a solution of methyl 4-bromopicolinate (1.0 g, 5.0 mmol) in DCM (500 mL) and DMF (20 mL) was added 4-isopropyl-3-methylbenzenamine hydrochloride (1.08 g, 5.90 mmol), HATU (3.8 g, 10 mmol), DIPEA (4.9 mL, 30 mmol) and the mixture was stirred at reflux overnight. After cooling to room temperature and evaporation of the solvent, the residue was purified by combi-flash (ISCO, 40 g silica, UV254, 3:1 pet ether/ethyl acetate) to afford 4-bromo-N-(4-isopropyl-3-methylphenyl)picolinamide (1.32 g, 80% yield) as a yellow oil: MS (ES) m/z 333 (M+H).

Step 6: Benzyl (2′-((4-isopropyl-3-methylphenyl)carbamoyl)-6-methoxy-[3,4′-bipyridin]-5-yl)carbamate

To a solution of benzyl (2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)carbamate (180 mg, 0.47 mmol) in EtOH (4 mL) and toluene (16 mL) was added 4-bromo-N-(4-isopropyl-3-methylphenyl)picolinamide (0.23 g, 0.70 mmol), Pd(PPh₃)₄ (5.4 mg, 0.046 mmol), and 2M K₂CO₃ in water (0.46 mL). The mixture was stirred at 100° C. overnight under nitrogen. After cooling to room temperature and evaporation of the solvent, the residue was purified by combi-flash (ISCO, 40 g silica, UV254, 3:1 pet ether/ethyl acetate) to afford benzyl (2′-((4-isopropyl-3-methylphenyl)carbamoyl)-6-methoxy-[3,4′-bipyridin]-5-yl)carbamate (216 mg, 90% yield) as a yellow solid: MS (ES) m/z 511 (M+H).

Step 7: Benzyl (2′-((4-isopropyl-3-methylphenyl)carbamoyl)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-5-yl)carbamate

To a solution of benzyl (2′-(((4-isopropyl-3-methylphenyl)carbamoyl)-6-methoxy-[3,4′-bipyridin]-5-yl)carbamate (216 mg, 0.42 mmol) in MeCN (50 mL) was added trimethylsilylchloride (0.18 mL, 2.1 mmol), sodium iodide (317 mg, 2.10 mmol), and the mixture was stirred at RT for 1.5 h. The precipitate was then collected by filtration. This solid was dissolved in a mixture of MeCN (1 mL) and water (50 mL) and then added to a solution of saturated aq. NaHCO₃ (10 mL). The suspension was then stirred for 30 min, filtered and dried to afford benzyl (2′-(((4-isopropyl-3-methylphenyl)carbamoyl)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-5-yl)carbamate (210 mg, 99% yield) as a yellow solid: MS (ES) m/z 497 (M+H).

Step 8: 5-Amino-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide

To a solution of benzyl (2′-((4-isopropyl-3-methylphenyl)carbamoyl)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-5-yl)carbamate (210 mg, 0.420 mmol) in MeOH (100 mL) was added Pd(OH)₂/C (21 mg) and the mixture stirred overnight at RT under hydrogen. The Pd(OH)₂/C was removed by filtration and the solvent evaporated to afford 5-amino-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide (120 mg, 80% yield) as a grey solid: ¹H NMR (400 MHz, CDCl₃) δ 9.96 (s, 1H), 8.57 (s, 1H), 8.36 (s, 1H), 7.48 (s, 2H), 7.45 (s, 1H), 7.00 (d, J=2.8 Hz, 1H), 6.85 (s, 1H), 4.40 (s, 1H), 2.87-2.92 (m, 1H), 2.37 (s, 3H), 1.27 (d, J=6.8 Hz, 6H); MS (ES) m/z 363 (M+H).

Step 9: 5-(Azetidin-3-ylamino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride

To a solution of 5-amino-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide (3.90 g, 10.8 mmol) in MeOH (500 mL) was added tert-butyl 3-oxoazetidine-1-carboxylate (2.76 g, 16.1 mmol), ZnCl₂ (14.7 g, 108 mmol) and NaCNBH₃ (2.03 g, 32.3 mmol). The mixture was stirred overnight at reflux. After cooling to room temperature, the solvent was allowed to evaporate and then HCl in dioxane was added to attain a pH of 1. The solid was removed and the solvent concentrated to give crude product, which was purified by Prep. HPLC to afford 5-(azetidin-3-ylamino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride (1.0 g, 25% yield) as a yellow solid: ¹H NMR (400 MHz, MeOD) δ 8.59 (d, J=5.2 Hz, 1H), 8.25 (d, J=1.2 Hz, 1H), 7.69 (dd, J=2.0, 5.2 Hz, 1H), 7.40 (s, 1H), 7.35 (s, 1H), 7.32 (d, J=2.0 Hz, 1H), 6.81 (s, 1H), 6.66 (d, J=11.6 Hz, 2H), 2.80 (m, 1H), 2.26 (s, 3H), 1.18 (d, J=6.8 Hz, 6H); MS (ES) m/z 417 (M+H).

Step 10: 5-((1-Acryloylazetidin-3-yl)amino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride

To a solution of 5-(azetidin-3-ylamino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride (60 mg, 0.14 mmol) in DCM (20 mL) was added acryloyl chloride (0.14 mL, 0.17 mmol) and TEA (0.1 mL, 0.7 mmol)). The mixture was stirred overnight at RT. The reaction was quenched by addition of MeOH (2 mL) and 4M HCl in 1,4-dioxane (2 mL). Water was added, the mixture extracted several times with ethyl acetate, the organic layers dried (MgSO₄), filtered and concentrated. The residue was purified by Prep. HPLC (pH<7) and converted to the HCl salt to afford 5-(((1-acryloylazetidin-3-yl)amino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide hydrochloride (16 mg, 24% yield) as a yellow solid: ¹H NMR (400 MHz, MeOD) δ 8.70 (d, J=4.8 Hz, 1H), 8.37 (d, J=1.2 Hz, 1H), 7.81 (dd, J=1.6, 5.2 Hz, 1H), 7.52 (s, 1H), 7.47 (s, 1H), 7.41 (d, J=1.6 Hz, 1H), 6.92 (s, 1H), 6.74 (d, J=2.4 Hz, 1H), 6.41 (dd, J=10.0, 16.8 Hz, 1H), 6.28 (dd, J=2.0, 16.8 Hz, 1H), 5.78 (dd, J=2.0, 10 Hz, 1H), 4.78-4.81 (m, 1H), 4.52-4.59 (m, 2H), 4.23-4.27 (m, 1H), 4.02-4.04 (m, 1H), 2.90-2.94 (m, 1H), 2.38 (s, 3H), 1.29 (d, J=6.8 Hz, 6H); MS (ES) m/z 472 (M+H).

Example 17 5-((1-(2-Chloroacetyl)azetidin-3-yl)amino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide formate

Following Example 16 but substituting 2-chloroacetyl chloride for acryloyl chloride in Step 10 afforded 5-((1-(2-chloroacetyl)azetidin-3-yl)amino)-N-(4-isopropyl-3-methylphenyl)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-2′-carboxamide formate (26 mg, 24% yield) as a yellow solid: ¹H NMR (400 MHz, MeOD) δ 8.70 (d, J=5.6 Hz, 1H), 8.37 (s, 1H), 7.80 (dd, J=2.0, 4.8 Hz, 1H), 7.52 (s, 1H), 7.48 (s, 1H), 7.41 (d, J=2.4 Hz, 1H), 6.92 (s, 1H), 6.73 (d, J=2.4 Hz, 1H), 4.76-4.80 (m, 1H), 4.52-4.59 (m, 2H), 4.24-4.27 (m, 1H), 4.11 (s, 2H), 4.01-4.02 (m, 1H), 2.90-2.94 (m, 1H), 2.38 (s, 3H), 1.30 (d, J=6.8 Hz, 6H); MS (ES) m/z 494 (M+H).

Example 18 (E)-2′-(Methylamino)-5-((1-(pent-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

To a solution of 5-(azetidin-3-ylamino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one di-hydrobromide (Example 14, Step 4, 80 mg, 0.19 mmol), in DMF (1 mL) was added (E)-pent-2-enoic acid (28 mg 0.28 mmol), HATU (105 mg, 0.277 mmol), and DIPEA (120 mg, 0.923 mmol). The reaction mixture was stirred at RT under nitrogen for 16 h. The residue was purified by Prep. HPLC to afford (E)-2′-(methylamino)-5-(1-(pent-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one (34 mg, 42%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 12.02 (s, 1H), 8.10 (d, J=5.3 Hz, 1H), 7.11 (d, J=2.1 Hz, 1H), 6.97 (dt, J=15.3, 6.4 Hz, 1H), 6.62 (dd, J=5.3, 1.6 Hz, 1H), 6.38 (d, J=1.8 Hz, 2H), 5.85 (dt, J=15.3, 1.7 Hz, 1H), 5.48 (d, J=6.6 Hz, 1H), 4.80 (d, J=5.5 Hz, 1H), 4.60 (t, J=7.9 Hz, 1H), 4.55-4.46 (m, 1H), 4.33 (dt, J=12.5, 6.3 Hz, 1H), 4.07 (m, 2H), 2.97 (d, J=4.9 Hz, 3H), 2.22 (m, 2H), 1.06 (t, J=7.4 Hz, 3H); MS (ES) m/z 354 (M+H).

Example 19 (E)-5-(1-(4-(Dimethylamino)but-2-enoyl)azetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one

Following Example 18 but substituting (E)-4-(dimethylamino)but-2-enoic acid for (E)-pent-2-enoic acid, afforded (E)-5-((1-(4-(dimethylamino)but-2-enoyl)azetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one (36 mg, 51%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 11.39 (s, 1H), 8.11 (d, J=5.3 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 6.90 (dt, J=15.4, 5.9 Hz, 1H), 6.62 (dd, J=5.3, 1.5 Hz, 1H), 6.39-6.37 (m, 1H), 6.36 (d, J=2.2 Hz, 1H), 6.05 (dt, J=15.3, 1.6 Hz, 1H), 5.47 (d, J=6.6 Hz, 1H), 4.72 (d, J=5.4 Hz, 1H), 4.62 (t, J=7.9 Hz, 1H), 4.55-4.47 (m, 1H), 4.39-4.30 (m, 1H), 4.12 (dd, J=8.8, 4.8 Hz, 1H), 4.04 (dd, J=10.7, 4.8 Hz, 1H), 3.07 (dd, J=6.1, 1.6 Hz, 2H), 2.97 (d, J=5.0 Hz, 3H), 2.25 (s, 6H); MS (ES) m/z 383 (M+H).

Example 20 (E)-2′-(Methylamino)-5-O-(5-phenoxypent-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one

Following Example 18 but substituting (E)-5-phenoxypent-2-enoic acid for (E)-pent-2-enoic acid afforded (E)-2′-(methylamino)-5-((1-(5-phenoxypent-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one (42 mg, 51%) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 12.25 (s, 1H), 8.09 (d, J=5.3 Hz, 1H), 7.32-7.20 (m, 2H), 7.11 (d, J=2.2 Hz, 1H), 7.02-6.90 (m, 2H), 6.90-6.84 (m, 2H), 6.61 (dd, J=5.5, 1.6 Hz, 1H), 6.41-6.33 (m, 2H), 6.01 (dt, J=15.5, 1.6 Hz, 1H), 5.55 (d, J=6.7 Hz, 1H), 4.87 (q, J=5.2 Hz, 1H), 4.59 (t, J=7.7 Hz, 1H), 4.50 (dd, J=10.7, 7.5 Hz, 1H), 4.38-4.28 (m, 1H), 4.13-4.02 (m, 4H), 2.96 (d, J=5.0 Hz, 3H), 2.76-2.61 (m, 2H); MS (ES) m/z 446 (M+H).

The following compounds were made by the general methods described above.

TABLE 1 Compound Examples-Spectral Data Example Structure Name Spectral Data 7

5-((1-acryloylazetidin-3-yl) amino)-2′-methyl-[3,4′- bipyridin]-6(1H)-one ¹H NMR (300 MHz, DMSO) δ 8.37-8.38 (m, 1 H), 7.39-7.48 (m, 2 H), 7.27 (s, 1 H), 6.50 (s, 1 H), 6.20-6.34 (m, 2 H), 6.08-6.22 (d, 1 H), 5.65-5.67 (d, 1 H), 5.65- 5.75 (d, 1 H), 4.59-4.63 (t, 1 H), 4.26-4.34 (m, 2 H), 4.08-4.13 (t, 1 H), 3.86-3.91 (m, 1 H), 2.48-2.50 (m, 3 H); MS (ES) m/z 311 (M + H). 8

3-((1-acryloylazetidin-3-yl) amino)-5-(6-methoxypyrazin- 2-yl)pyridin-2(1H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 8.13 (s, 1 H), 7.75 (s, 1 H), 7.48-7.49 (m, 1 H), 6.98 (m, 1 H), 6.75 (s, 1 H), 6.29-6.36 (m, 1 H), 6.07-6.20 (m, 2 H), 5.64-5.75 (d, 1 H), 4.33-4.57 (t, 1 H), 4.26-4.30 (m, 2 H), 4.11-4.14 (m, 1 H), 3.82- 3.93 (m, 1 H), 3.37-3.49 (m, 1 H), 2.84-2.85 (m, 3 H); MS (ES) m/z 328 (M + H). 9

5-((1-acryloylazetidin-3-yl) amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one ¹H NMR (300 MHz, DMSO) δ 7.93-7.95 (d, 1 H), 7.08 (s, 1 H), 6.67-6.69 (d, 1 H), 6.54 (s, 1 H), 6.31-6.35 (m, 3 H), 6.22-6.44 (d, 1 H), 6.14-6.12 (m, 1 H), 5.65- 5.75 (d, 1 H), 4.56-4.60 (m, 1 H), 4.26-4.34 (m, 2 H), 4.11-4.14 (m, 1 H), 3.89-3.91 (m, 1 H), 2.78-2.79 (m, 3 H); MS (ES) m/z 326 (M + H). 10

3-((1-acryloylazetidin-3-yl) amino)-5-(2-(methylamino) pyrimidin-4-yl)pyridin- 2(1H)-one ¹H NMR (300 MHz, DMSO) δ 11.84 (s, 1 H), 8.22 (m, 1 H), 7.03-7.57 (m, 2 H), 6.77-6.99 (m, 2 H), 6.29 (s, 1 H), 6.21- 6.23 (m, 1 H), 6.08-6.09 (m, 1 H), 5.83-6.08 (d, 1 H), 5.65- 5.82 (d, 1 H), 4.49-4.56 (t, 1 H), 4.08-4.21 (m, 2 H), 3.81- 3.94 (m, 1 H), 3.86-3.91 (m, 1 H), 2.83-2.84 (m, 3 H); MS (ES) m/z 327 (M + H). 11

3-((1-acryloylazetidin-3-yl) amino)-5-(6-(methylamino) pyrazin-2-yl)pyridin-2(1H)- one ¹H NMR (400 MHz, DMSO- d₆) δ 8.68 (s, 1 H), 8.12 (s, 1 H), 7.60-7.61 (m, 1 H), 6.80 (s, 1 H), 6.29-6.39 (m, 2 H), 6.08-6.12 (d, 1 H), 5.64-5.68 (d, J = 16 Hz, 1 H), 4.36-4.50 (t, 1 H), 4.27-4.36 (m, 2 H), 4.12-4.15 (m, 1 H), 3.91-3.97 (m, 4 H), 3.07 (br s, 1 H); MS (ES) m/z 327 (M + H). 12

(E)-N-methyl-4-oxo-4-(3- ((6-oxo-1,6-dihydro-[3,4′- bipyridin]-5-yl)amino) azetidin-1-yl)but-2-enamide ¹H NMR (400 MHz, DMSO-d₆) δ 8.50-8.56 (m, 3 H), 7.60-7.62 (m, 1 H), 7.29-7.30 (m, 1 H), 6.49-6.50 (s, 1 H), 6.17-6.20 (m, 2 H), 6.04-6.07 (d, 1 H), 4.27- 4.41 (m, 3 H), 3.86-3.95 (d, 2 H), 2.64-2.68 (m, 3 H), 1.22 (m, 3 H); MS (ES) m/z 354 (M + H). 13

(E)-5-((1-(4-(methylamino) but-2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one ¹H NMR (400 MHz, DMSO-d₆) δ 9.20 (br s, 2 H), 8.73-8.83 (m, 2 H), 8.3-8.31 (m, 2 H), 7.81 (br s, 1 H), 6.59-6.76 (m, 2 H), 6.38-6.42 (d, 1 H), 4.47-4.63 (t, 1 H), 4.35-4.44 (m, 1 H), 4.16-4.28 (t, 1 H), 4.09-4.1 (t, 1 H), 3.89-3.95 (m, 2 H), 3.38 (s, 1 H); MS (ES) m/z 340 (M + H). The following compounds can generally be made using the methods described above. It is expected that these compounds when made will have activity similar to those that have been prepared. The following compounds are represented herein using the Simplified Molecular Input Line Entry System, or SMILES. SMILES is a modern chemical notation system, developed by David Weininger and Daylight Chemical Information Systems, Inc., that is built into all major commercial chemical structure drawing software packages. Software is not needed to interpret SMILES text strings, and an explanation of how to translate SMILES into structures can be found in Weininger, D., J. Chem. Inf. Comput. Sci. 1988, 28, 31-36. All SMILES strings used herein, as well as many IUPAC names, were generated using CambridgeSoft's ChemDraw 10.0.

TABLE 2 Compound Examples Exam- ple Structure Name 1

(R)-5-((1-(2-chloroacetyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6- (1H)-one 2

(R)-5-((1-acryloylpiperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 3

(R)-5-((1-acryloylpyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 4

5-((1-(2-chloroacetyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 5

5-((1-acryloylazetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 6

(E)-5-((1-(but-2-enoyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 7

5-((1-acryloylazetidin-3-yl)amino)- 2′-methyl-[3,4′-bipyridin]-6(1H)-one 8

3-((1-acryloylazetidin-3-yl)amino)-5- (6-methoxypyrazin-2-yl)pyridin- 2(1H)-one 9

5-((1-acryloylazetidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one 10

3-((1-acryloylazetidin-3-yl)amino)- 5-(2-(methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 11

3-((1-acryloylazetidin-3-yl)amino)-5- (6-(methylamino)pyrazin-2-yl) pyridin-2(1H)-one 12

(E)-N-methyl-4-oxo-4-(3-((6-oxo- 1,6-dihydro-[3,4′-bipyridin]-5-yl) amino)azetidin-1-yl)but-2-enamide 13

(E)-5-((1-(4-(methylamino)but-2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 14

(E)-5-((1-cinnamoylazetidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 15

(E)-2′-(methylamino)-5-((1- (4-phenylbut-2-enoyl) azetidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 16

5-((1-acryloylazetidin-3-yl)amino)- N-(4-isopropyl-3-methylphenyl)- 6-oxo-1,6-dihydro-[3,4′-bipyridin]- 2′-carboxamide hydrochloride 17

5-((1-(2-chloroacetyl)azetidin- 3-yl)amino)-N-(4-isopropyl- 3-methylphenyl)-6-oxo-1,6- dihydro-[3,4′-bipyridine]-2′- carboxamide formate 18

(E)-2′-(methylamino)-5-((1-(pent- 2-enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 19

(E)-5-((1-(4-(dimethylamino)but- 2-enoyl)azetidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 20

(E)-2′-(methylamino)-5- ((1-(5-phenoxypent- 2-enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 21

(E)-2-(3-((2′-(methylamino)-6-oxo- 1,6-dihydro-[3,4′-bipyridin]-5-yl)amino)azetidine- 1-carbonyl)but-2-enenitrile 22

(E)-2-(3-((6-oxo-1,6-dihydro-[3,4′- bipyridin]-5-yl)amino)azetidine- 1-carbonyl)but-2-enenitrile 23

(E)-2′-(methylamino)-5-((1- (3-(pyridin-2-yl)acryloyl) azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 24

(E)-2′-(methylamino)-5-((1- (4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 25

(E)-2′-(methylamino)-5- ((1-(4-(methylamino) but-2-enoyl)piperidin-4- yl)amino)-[3,4′-bipyridin]- 6(1H)-one 26

(E)-2′-(methylamino)-5-((1- (4-(piperidin-1-yl)but-2- enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 27

(E)-2′-(methylamino)-5-((1- (4-(pyridin-2-yl)but-2- enoyl)azetidin-3-yl)amino- [3,4′-bipyridin]-6(1H)-one 28

(E)-2′-(methylamino)-5-((1-(4- (pyrrolidin-1-yl)but-2-enoyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 29

(E)-2′-(methylamino)-5-((1- (4-(tetrahydro- 2H-pyran-4-yl)but-2-enoyl) azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 30

(E)-2′-(methylamino)-5-((1-(4-morpholinobut- 2-enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 31

(E)-2′-methoxy-5-((1- (4-(methylamino)but- 2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 32

(E)-2′-methoxy-5-((1- (4-(methylamino)but-2- enoyl)piperidin-4-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 33

(E)-3-((1-(4-(dimethylamino) but-2-enoyl) azetidin-3-yl)(methyl)amino)- 5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 34

(E)-3-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl) (methyl)amino)-5- (6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 35

(E)-3-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl)(methyl)amino)-5-(6-(methylamino)pyrazin-2-yl) pyridin-2(1H)-one 36

(E)-3-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl) (methyl)amino)-5-(2- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 37

(E)-3-((1-(4-(dimethylamino) but-2-enoyl) azetidin-3-yl)(methyl)amino)-5-(6- methoxypyrazin-2-yl)pyridin- 2(1H)-one 38

(E)-3-((1-(4-(dimethylamino) but-2-enoyl) azetidin-3-yl)(methyl)amino)-5-(2- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 39

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)- 5-(pyrazin-2-yl)pyridin-2(1H)-one 40

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)-5- (pyrimidin-4-yl)pyridin-2(1H)-one 41

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(2- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 42

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(2- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 43

(E)-3-((1-(4-(dimethylamino) but-2-enoyl) azetidin-3-yl)amino)-5- (6-(methylamino) pyrimidin-4-yl)pyridin-2(1H)-one 44

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(6- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 45

(E)-3-((1-(4-(dimethylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(6- (methylamino)pyrazin-2-yl)pyridin- 2(1H)-one 46

(E)-3-((1-(4-(dimethylamino) but-2-enoyl) azetidin-3-yl)amino)-5- (6-methoxypyrazin- 2-yl)pyridin-2(1H)-one 47

(E)-3-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl)amino)- 5-(pyrazin-2-yl)pyridin- 2(1H)-one 48

(E)-3-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl) amino)-5-(pyrimidin-4-yl) pyridin-2(1H)-one 49

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)- 5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 50

(E)-3-((1-(4-(isopropylamino) but-2-enoyl) azetidin-3-yl)(methyl)amino)- 5-(6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 51

(E)-3-((1-(4-(isopropylamino) but-2-enoyl) azetidin-3-yl)(methyl)amino)- 5-(6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 52

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)- 5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 53

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)- 5-(6-methoxypyrazin-2-yl)pyridin- 2(1H)-one 54

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)(methyl)amino)- 5-(2-methoxypyrimidin-4-yl)pyridin- 2(1H)-one 55

(E)-3-((1-(4-(isopropylamino)but- 2-enoyl)azetidin-3-yl)(methyl) amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 56

(E)-3-((1-(4-(isopropylamino)but- 2-enoyl)azetidin-3-yl)(methyl) amino)-5-(pyrimidin-4-yl) pyridin-2(1H)-one 57

(E)-3-((1-(4-(isopropylamino)but- 2-enoyl)azetidin-3-yl)amino)-5-(6- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 58

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(6- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 59

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(6- (methylamino)pyrazin-2-yl)pyridin- 2(1H)-one 60

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(2- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 61

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(6- methoxypyrazin-2-yl)pyridin-2(1H)-one 62

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(2- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 63

(E)-3-((1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)-5- (pyrazin-2-yl)pyridin-2(1H)-one 64

(E)-3-((1-(4-(isopropylamino)but- 2-enoyl)azetidin-3-yl)amino)- 5-(pyrimidin-4-yl)pyridin- 2(1H)-one 65

(E)-3-((1-(4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)-5-(2- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 66

(E)-3-((1-(4-(methylamino)but- 2-enoyl)azetidin-3-yl)amino)-5- (6-(methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 67

(E)-3-((1-(4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)-5- (6-(methylamino)pyrazin-2-yl) pyridin-2(1H)-one 68

(E)-3-((1-(4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)-5- (pyrazin-2-yl)pyridin-2(1H)-one 69

(E)-3-((1-(4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)-5- (pyrimidin-4-yl)pyridin-2(1H)-one 70

(E)-3-((1-(4-aminobut-2-enoyl) azetidin-3-yl)(cyclopropylmethyl) amino)-5-(6-(methylamino) pyrimidin-4-yl)pyridin-2(1H)-one 71

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin-3- yl)(cyclopropylmethyl)amino)- 5-(6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 72

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl)amino)- 5-(6-(methylamino)pyrazin-2- yl)pyridin-2(1H)-one 73

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl)amino)- 5-(2-(methylamino)pyrimidin-4- yl)pyridin-2(1H)-one 74

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl)amino)-5- (6-methoxypyrazin-2-yl)pyridin- 2(1H)-one 75

(E)-3-((1-(4-aminobut-2-enoyl) azetidin-3-yl)(cyclopropylmethyl) amino)-5-(2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 76

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl)amino)-5- (pyrazin-2-yl)pyridin-2(1H)-one 77

(E)-3-((1-(4-aminobut-2-enoyl) azetidin-3-yl)(cyclopropylmethyl) amino)-5-(pyrimidin-4-yl)pyridin-2(1H)-one 78

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5- (2-(methylamino) pyrimidin-4-yl)pyridin- 2(1H)-one 79

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5-(2- methoxypyrimidin-4-yl)pyridin- 2(1H)-one 80

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5- (6-(methylamino) pyrimidin-4-yl)pyridin- 2(1H)-one 81

(E)-3-((1-(4-aminobut-2-enoyl) azetidin-3-yl)(methyl)amino)-5- (6-(methylamino)pyrazin-2-yl) pyridin-2(1H)-one 82

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5- (6-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 83

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5- (6-methoxypyrazin- 2-yl)pyridin-2(1H)-one 84

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)-5- (pyrazin-2-yl) pyridin-2(1H)-one 85

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(methyl)amino)- 5-(pyrimidin-4-yl) pyridin-2(1H)-one 86

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5- (2-(methylamino) pyrimidin-4-yl)pyridin- 2(1H)-one 87

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5- (2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 88

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 89

(E)-3-((1-(4-aminobut-2-enoyl) azetidin-3-yl)amino)-5- (6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 90

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5-(6- methoxypyrimidin- 4-yl)pyridin-2(1H)-one 91

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5-(6- methoxypyrazin- 2-yl)pyridin-2(1H)-one 92

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5-(pyrazin-2-yl) pyridin-2(1H)-one 93

(E)-3-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-5-(pyrimidin-4-yl) pyridin-2(1H)-one 94

(E)-3-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 95

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (6-methoxypyrimidin- 4-yl)pryidin-2(1H)-one 96

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6-methylamino)pyrimidin- 2-yl)pyridin-2(1H)-one 97

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (2-(methylamino) pyrimidin-4-yl)pyridin-2(1H)-one 98

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (6-methoxypyrazin-2- yl)pyridin-2(1H)-one 99

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 100

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(pyrazin- 2-yl)pyridin-2(1H)-one 101

(E)-3-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (pyrimidin-4-yl) pyridin-2(1H)-one 102

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6- (methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 103

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6- methoxypyrimidin-4- yl)pyridin-2(1H)-one 104

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-5- (6-(methylamino) pyrazin-2-yl)pyridin-2(1H)-one 105

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(2-(methylamino) pyrimidin-4-yl)pyridin-2(1H)-one 106

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(6-methoxypyrazin-2- yl)pyridin-2(1H)-one 107

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 108

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 109

(E)-3-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(pyrimidin-4-yl)pyridin- 2(1H)-one 110

(E)-3-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6- (methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 111

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(6-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 112

(E)-3-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-5-(6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 113

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(2-(methylamino) pyrimidin-4-yl)pyridin-2(1H)-one 114

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(6-methoxypyrazin-2- yl)pyridin-2(1H)-one 115

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 116

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 117

(E)-3-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)azetidin- 3-yl)amino)-5-(pyrimidin-4-yl) pyridin-2(1H)-one 118

(E)-3-(5-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl)amino)-6- oxo-1,6-dihydropyridin-3-yl)-N-(4- isopropyl-3-methylphenyl)-5- methylbenzamide 119

(E)-3-(5-((1-(4-(dimethylamino)but- 2-enoyl)azetidin-3-yl)amino)-6-oxo- 1,6-dihydropyridin-3-yl)-N-(4- isopropyl-3-methylphenyl)benzamide 120

(E)-3-(methyl(1-(4-(methylamino)but- 2-enoyl)azetidin-3-yl)amino)-5-(6- (methylamino)pyrimidin-4- yl)pyridin-2(1H)-one 121

(E)-3-(methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- 5-(6-(methylamino)pyrazin-2- yl)pyridin-2(1H)-one 122

(E)-3-(methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- 5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 123

(E)-3-(methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- 5-(pyrazin-2-yl)pyridin-2(1H)-one 124

(E)-3-(methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- 5-(pyrimidin-4-yl)pyridin-2(1H)- one 125

(E)-3-cyano-5-(5-((1- (4-(dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-6-oxo- 1,6-dihydropyridin-3-yl)- N-(4-isopropyl-3-methylphenyl)benzamide 126

(E)-4-(methylamino)-5′- ((1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- [2,3′-bipyridin]-6′(1′H)-one 127

(E)-4-methoxy-5′- ((1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)- [2,3′-bipyridin]-6′(1′H)-one 128

(E)-5′-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl) amino)-[2,3′-bipyridin]- 6′(1′H)-one 129

(E)-5-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 130

(E)-5-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl) amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 131

(E)-5′-((1-(4-(dimethylamino)but- 2-enoyl)azetidin-3-yl)amino)- 4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 132

(E)-5′-((1-(4-(dimethylamino) but-2-enoyl)azetidin-3-yl)amino)- 4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 133

(E)-5-((1-(4-(dimethylamino) but-2-enoyl) piperidin-4-yl)(ethyl)amino)- 2′-(methylamino)- [3,4′-bipyridin]- 6(1H)-one 134

(E)-5-((1-(4-(dimethylamino) but-2-enoyl) piperidin-4-yl)(ethyl)amino)- 2′-methoxy- [3,4′-bipyridin]-6(1H)-one 135

(E)-5-((1-(4-(dimethylamino) but-2-enoyl) piperidin-4-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 136

(E)-5-((1-(4-(dimethylamino) but-2-enoyl) piperidin-4-yl)amino)-[3,4′- bipyridin]-6(1H)-one 137

(E)-5-((1-(4-(dimethylamino) but-2-enoyl)piperidin-4-yl) amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 138

(E)-5-((1-(4-(dimethylamino) but-2-enoyl)piperidin-4-yl) amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 139

(E)-5′-((1-(4-(isopropylamino) but-2-enoyl)azetidin-3-yl) amino)-[2,3′-bipyridin]- 6′(1′H)-one 140

(E)-5-((1-(4-(isopropylamino) but-2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 141

(E)-5-((1-(4-(isopropylamino) but-2-enoyl)azetidin-3-yl) amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 142

(E)-5-((1-(4-(isopropylamino) but-2-enoyl)azetidin-3-yl) amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 143

(E)-5′-((1-(4-(isopropylamino) but-2-enoyl)azetidin-3-yl) amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 144

(E)-5′-((1-(4-(isopropylamino) but-2-enoyl) azetidin-3-yl)amino)-4-methoxy- [2,3′-bipyridin]-6′(1′H)-one 145

(E)-5-((1-(4-(isopropylamino) but-2-enoyl) piperidin-4-yl)amino)-[3,4′- bipyridin]-6(1H)-one 146

(E)-5-((1-(4-(isopropylamino) but-2-enoyl)piperidin- 4-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 147

(E)-5-((1-(4-(isopropylamino) but-2-enoyl)piperidin-4-yl) amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 148

(E)-5′-((1-(4-(methylamino) but-2-enoyl)azetidin-3-yl) amino)-[2,3′-bipyridin]- 6′(1′H)-one 149

(E)-5-((1-(4-(methylamino) but-2-enoyl)piperidin-4-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 150

(E)-5-((1-(4-(piperidin-1-yl) but-2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 151

(E)-5-((1-(4-(pyridin-2-yl)but-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 152

(E)-5-((1-(4-(pyrrolidin-1-yl) but-2-enoyl)azetidin-3-yl) amino)-[3,4′-bipyridin]- 6(1H)-one 153

(E)-5-((1-(4-(tetrahydro- 2H-pyran-4-yl) but-2-enoyl)azetidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 154

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl)amino)-4- (methylamino)-[2,3′-bipyridin]- 6′(1′H)-one 155

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin-3-yl) (cyclopropylmethyl)amino)- 4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 156

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin-3-yl) (cyclopropylmethyl)amino)- [2,3′-bipyridin]-6′(1′H)-one 157

(E)-5-((1-(4-aminobut- 2-enoyl)azetidin-3-yl) (cyclopropylmethyl)amino)- 2′-(methylamino)- [3,4′-bipyridin]- 6(1H)-one 158

(E)-5-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 159

(E)-5-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]- 6(1H)-one 160

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin-3-yl) amino)-[2,3′-bipyridin]- 6′(1′H)-one 161

(E)-5-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 162

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-2′-(methylamino) [3,4′-bipyridin]-6(1H)-one 163

(E)-5-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 164

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-4-(methylamino) [2,3′-bipyridin]-6′(1′H)-one 165

(E)-5′-((1-(4-aminobut- 2-enoyl)azetidin- 3-yl)amino)-4-methoxy- [2,3′-bipyridin]-6′(1′H)-one 166

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)(cyclopropylmethyl) amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 167

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 168

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]- 6(1H)-one 169

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin-4-yl) (ethyl)amino)-[3,4′- bipyridin]-6(1H)-one 170

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)(ethyl)amino)-2′- (methylamino)-[3,4′- bipyridin]-6(1H)-one 171

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)(ethyl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 172

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 173

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 174

(E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 4-yl)amino)-2′-methoxy- [3,4′-bipyridin]- 6(1H)-one 175

(E)-5-((1-(4-cyclohexylbut-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 176

(E)-5-((1-(4-cyclohexylbut-2-enoyl) azetidin-3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 177

(E)-5-((1-(4-isoproproxybut-2-enoyl) azetidin-3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 178

(E)-5-((1-(4-methoxybut-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 179

(E)-5-((1-(4-methoxybut-2-enoyl) azetidin-3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 180

(E)-5-((1-(4-morpholinobut-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 181

(E)-5-((1-(4-phenylbut- 2-enoyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 182

(E)-5′-((cyclopropylmethyl)(1-(4- dimethylamino)but-2-enoyl)azetidin- 3-yl)amino)-4-(methylamino)-[2,3′- bipyridin]-6′(1′H)-one 183

(E)-5′-((cyclopropylmethyl) (1-(4-dimethylamino)but-2- enoyl)azetidin-3-yl)amino)- 4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 184

(E)-5′-((cyclopropylmethyl)(1- (4-dimethylamino) but-2-enoyl)azetidin- 3-yl)amino)-[2,3′-bipyridin]- 6′(1′H)-one 185

(E)-5-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-2′- methylamino)-[3,4′-bipyridin]- 6(1H)-one 186

(E)-5′-((cyclopropylmethyl) (1-(4-(dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 187

(E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 188

(E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-4-yl)amino)-2′- (methylamino)-[3,4′- bipyridin]-6(1H)-one 189

(E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-4-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 190

(E)-5-((cyclopropylmethyl) (1-(4-(dimethylamino)but-2-enoyl) piperidin-4-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 191

(E)-5′-((cyclopropylmethyl) (1-(4-(isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 192

(E)-5′-((cyclopropylmethyl) (1-(4-(isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-4-methoxy-[2,3′- bipyridin]-6′(1′H)-one 193

(E)-5′-((cyclopropylmethyl) (1-(4-(isopropylamino)but-2- enoyl)azetidin-3-yl)amino)- [2,3′-bipyridin]-6′(1′H)-one 194

(E)-5-((cyclopropylmethyl)(1- (4-(isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 195

(E)-5-((cyclopropylmethyl)(1- (4-(isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 196

(E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but-2-enoyl) azetidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 197

(E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but-2-enoyl) piperidin-4-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 198

(E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 4-yl)amino)-2′-methoxy[3,4′- bipyridin]-6(1H)-one 199

(E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 4-yl)amino)-[3,4′-bipyridin]-6(1H)-one 200

(E)-5′-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 201

(E)-5′-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-4-methoxy- [2,3′-bipyridin]-6′(1′H)-one 202

(E)-5′-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-[2,3′-bipyridin]- 6′(1′H)-one 203

(E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl) azetidin-3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 204

(E)-5-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 205

(E)-5-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl)azetidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 206

(E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 4-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 207

(E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 4-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 208

(E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 4-yl)amino)-[3,4′-bipyridin]-6(1H)-one 209

(E)-5-(2-methoxypyrimidin-4-yl)- 3-((1-(4-(methylamino)but- 2-enoyl)azetidin- 3-yl)amino)pyridin-2(1H)-one 210

(E)-5-(2-methoxypyrimidin-4-yl)- 3-(methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl)amino)pyridin-2(1H)-one 211

(E)-5-(6-methoxypyrazin-2-yl)-3-((1- (4-(methylamino)but-2-enoyl)azetidin- 3-yl)amino)pyridin-2(1H)-one 212

(E)-5-(6-methoxypyrazin-2-yl)-3- (methyl(1-(4-(methylamino) but-2-enoyl)azetidin-3-yl) amino)pyridin-2(1H)-one 213

(E)-5-(6-methoxypyrimidin-4-yl)-3- ((1-(4-(methylamino)but-2-enoyl) azetidin-3-yl)amino)pyridin-2(1H)- one 214

(E)-5-(6-methoxypyrimidin-4-yl)- 3-(methyl(1-(4-(methylamino)but-2- enoyl)azetidin-3-yl)amino)pyridin- 2(1H)-one 215

(E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-4-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 216

(E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-4-yl)amino)- 2′-methoxy-[3,4′-bipyridin]-6(1H)-one 217

(E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-4-yl)amino)- [3,4′-bipyridin]-6(1H)-one 218

(E)-5-(ethyl(1-(4-(methylamino)but- 2-enoyl)piperidin-4-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 219

(E)-5-(ethyl(1-(4-(methylamino)but- 2-enoyl)piperidin-4-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 220

(E)-5-(ethyl(1-(4-(methylamino)but- 2-enoyl)piperidin-4-yl)amino)-[3,4′- bipyridin]-6(1H)-one 221

(R)-5-((1-(2-chloroacetyl)piperidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 222

(R)-5-((1-(2-chloroacetyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 223

(R)-5-((1-(2-chloroacetyl)pyrrolidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 224

(R)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)- [3,4′-bipyridin]-6(1H)-one 225

(R)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 226

(R)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 227

(R)-5-((1-acryloylpiperidin-3-yl) (ethyl)amino)-[3,4′-bipyridin]- 6(1H)-one 228

(R)-5-((1-acryloylpiperidin-3-yl) (ethyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 229

(R)-5-((1-acryloylpiperidin-3-yl) (ethyl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 230

(R)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-[3,4′-bipyridin]- 6(1H)-one 231

(R)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 232

(R)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 233

(R)-5-((1-acryloylpiperidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 234

(R)-5-((1-acryloylpiperidin-3-yl) amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 235

(R)-5-((1-acryloylpiperidin-3-yl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 236

(R)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-[3,4′- bipyridin]-6(1H)-one 237

(R)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 238

(R)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 239

(R)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-[3,4′-bipyridin]- 6(1H)-one 240

(R)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 241

(R)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 242

(R)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-[3,4′-bipyridin]- 6(1H)-one 243

(R)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 244

(R)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 245

(R)-5-((1-acryloylpyrrolidin-3-yl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 246

(R)-5-((1-acryloylpyrrolidin-3-yl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 247

(R,E)-2′-(methylamino)-5-((1-(4- (methylamino)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 248

(R,E)-2′-(methylamino)-5-((1-(4- (methylamino)but-2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 249

(R,E)-2′-(methylamino)-5- ((1-(4-(piperidin-1-yl)but-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 250

(R,E)-2′-(methylamino)-5-((1- (4-(piperidin-1-yl)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 251

(R,E)-2′-(methylamino)-5-((1-(4- (pyridin-2-yl)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)- one 252

(R,E)-2′-(methylamino)-5-((1-(4- (pyridin-2-yl)but-2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 253

(R,E)-2′-(methylamino)-5-((1- (4-(pyrrolidin-1-yl)but-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 254

(R,E)-2′-(methylamino)-5-((1-(4- (pyrrolidin-1-yl)but-2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 255

(R,E)-2′-(methylamino)-5-((1- (4-morpholinobut-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 256

(R,E)-2′-(methylamino)-5-((1- (4-morpholinobut-2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 257

(R,E)-2′-(methylamino)-5-((1-(4- phenylbut-2-enoyl)piperidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 258

(R,E)-2′-(methylamino)-5-((1-(4- phenylbut-2-enoyl)pyrrolidin-3- yl)amino)-[3,4′-bipyridin]-6(1H)-one 259

(R,E)-2′-methoxy-5-((1- (4-(methylamino) but-2-enoyl)piperidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)- one 260

(R,E)-2′-methoxy-5-((1-(4-(methylamino)but-2-enoyl) pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 261

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)piperidin-3-yl)(ethyl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 262

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)piperidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]- 6(1H)-one 263

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)piperidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 264

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 265

(R,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 266

(R,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 267

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)(ethyl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 268

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]- 6(1H)-one 269

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 270

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 271

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 272

(R,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 273

(R,E)-5-((1-(4-(isopropylamino)but-2- enoyl)piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 274

(R,E)-5-((1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl) amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 275

(R,E)-5-((1-(4-(isopropylamino)but-2- enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 276

(R,E)-5-((1-(4-(isopropylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 277

(R,E)-5-((1-(4-(isopropylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 278

(R,E)-5-((1-(4-(isopropylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 279

(R,E)-5-((1-(4-(methylamino)but- 2-enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 280

(R,E)-5-((1-(4-(methylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 281

(R,E)-5-((1-(4-(piperidin-1-yl)but- 2-enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 282

(R,E)-5-((1-(4-(piperidin-1-yl)but- 2-enoyl)pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 283

(R,E)-5-((1-(4-(pyridin-2-yl)but-2- enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 284

(R,E)-5-((1-(4-(pyridin-2-yl)but-2- enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 285

(R,E)-5-((1-(4-(pyrrolidin-1-yl)but-2- enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 286

(R,E)-5-((1-(4-(pyrrolidin-1-yl)but-2- enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 287

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 288

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 289

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]-6(1H)-one 290

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 291

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 292

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 293

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 294

(R,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 295

(R,E)-5-((1-(4-aminobut- 2-enoyl)piperidin- 3-yl)amino)-2′-methoxy- [3,4′-bipyridin]- 6(1H)-one 296

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 297

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 298

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]-6(1H)-one 299

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 300

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 301

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 302

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 303

(R,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 304

(R,E)-5-((1-(4-aminobut- 2-enoyl)pyrrolidin- 3-yl)amino)-2′-methoxy- [3,4′-bipyridin]- 6(1H)-one 305

(R,E)-5-((1-(4-morpholinobut-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 306

(R,E)-5-((1-(4-morpholinobut-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 307

(R,E)-5-((1-(4-phenylbut-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 308

(R,E)-5-((1-(4-phenylbut-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 309

(R,E)-5-((1-(but-2-enoyl) piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 310

(R,E)-5-((1-(but-2-enoyl)piperidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 311

(R,E)-5-((1-(but-2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 312

(R,E)-5-((1-(but-2-enoyl)pyrrolidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 313

(R,E)-5-((cyclopropylmethyl)(1-(4- (dimethylamino)but-2-enoyl) piperidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 314

(R,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-3-yl)amino)-2′-methoxy-[3,4′-bipyridin]-6(1H)-one 315

(R,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 316

(R,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 317

(R,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 318

(R,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 319

(R,E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but- 2-enoyl)piperidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 320

(R,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 321

(R,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 322

(R,E)-5-((cyclopropylmethyl)(1- (4-(isopropylamino)but-2-enoyl)pyrrolidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 323

(R,E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but- 2-enoyl)pyrrolidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 324

(R,E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but- 2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 325

(R,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but- 2-enoyl)piperidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 326

(R,E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 327

(R,E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 328

(R,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but- 2-enoyl)pyrrolidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 329

(R,E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)pyrrolidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 330

(R,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but- 2-enoyl)pyrrolidin-3- yl)amino)-[3,4′-bipyridin]- 6(1H)-one 331

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 332

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 333

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 334

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 335

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]- 6(1H)-one 336

(R,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 337

(R,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 338

(R,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 339

(R,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 340

(R,E)-5-(ethyl(1-(4-(methylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 341

(R,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)pyrrolidin-3-yl) amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 342

(R,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)pyrrolidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 343

(S)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)-[3,4′- bipyridin]-6(1H)-one 344

(S)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 345

(S)-5-((1-acryloylpiperidin-3-yl) (cyclopropylmethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 346

(S)-5-((1-acryloylpiperidin-3-yl) (ethyl)amino)-[3,4′-bipyridin]-6(1H)- one 347

(S)-5-((1-acryloylpiperidin-3-yl) (ethyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 348

(S)-5-((1-acryloylpiperidin-3-yl)(ethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 349

(S)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-[3,4′-bipyridin]- 6(1H)-one 350

(S)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 351

(S)-5-((1-acryloylpiperidin-3-yl) (methyl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 352

(S)-5-((1-acryloylpiperidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 353

(S)-5-((1-acryloylpiperidin-3-yl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 354

(S)-5-((1-acryloylpiperidin-3-yl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 355

(S)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-[3,4′- bipyridin]-6(1H)-one 356

(S)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]-6(1H)- one 357

(S)-5-((1-acryloylpyrrolidin-3-yl) (cyclopropylmethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 358

(S)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-[3,4′-bipyridin]-6(1H)- one 359

(S)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 360

(S)-5-((1-acryloylpyrrolidin-3-yl) (ethyl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 361

(S)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-[3,4′-bipyridin]- 6(1H)-one 362

(S)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 363

(S)-5-((1-acryloylpyrrolidin-3-yl) (methyl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 364

(S)-5-((1-acryloylpyrrolidin-3-yl) amino)-[3,4′-bipyridin]-6(1H)-one 365

(S)-5-((1-acryloylpyrrolidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 366

(S)-5-((1-acryloylpyrrolidin-3-yl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 367

(S,E)-2′-(methylamino)-5-((1-(4- (methylamino)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 368

(S,E)-2′-(methylamino)-5-((1- (4-(methylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 369

(S,E)-2′-methoxy-5-((1-(4- (methylamino)but-2-enoyl) piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 370

(S,E)-2′-methoxy-5-((1-(4- (methylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 371

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)(ethyl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 372

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)(ethyl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 373

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 374

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 375

(S,E)-5-((1-(4-(dimethylamino)but-2- enoyl)piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 376

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)piperidin-3-yl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 377

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)pyrrolidin-3-yl)(ethyl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 378

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)pyrrolidin-3-yl)(ethyl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 379

(S,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)(ethyl)amino)- [3,4′-bipyridin]-6(1H)-one 380

(S,E)-5-((1-(4-(dimethylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 381

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]- 6(1H)-one 382

(S,E)-5-((1-(4-(dimethylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 383

(S,E)-5-((1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 384

(S,E)-5-((1-(4-(isopropylamino)but- 2-enoyl)piperidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 385

(S,E)-5-((1-(4-(isopropylamino)but- 2-enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 386

(S,E)-5-((1-(4-(isopropylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 387

(S,E)-5-((1-(4-(isopropylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 388

(S,E)-5-((1-(4-(isopropylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 389

(S,E)-5-((1-(4-(methylamino)but-2- enoyl)piperidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 390

(S,E)-5-((1-(4-(methylamino)but-2- enoyl)pyrrolidin-3-yl)amino)-[3,4′- bipyridin]-6(1H)-one 391

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 392

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 393

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]-6(1H)-one 394

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)-[3,4′- bipyridin]-6(1H)-one 395

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 396

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 397

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 398

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]-6(1H)-one 399

(S,E)-5-((1-(4-aminobut-2-enoyl) piperidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 400

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 401

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 402

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(cyclopropylmethyl) amino)-[3,4′-bipyridin]-6(1H)-one 403

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)-[3,4′- bipyridin]-6(1H)-one 404

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 405

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)(ethyl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 406

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 407

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 408

(S,E)-5-((1-(4-aminobut-2-enoyl) pyrrolidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 409

(S,E)-5-((cyclopropylmethyl) (1-(4-(dimethylamino)but-2-enoyl) piperidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 410

(S,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 411

(S,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 412

(S,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 413

(S,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 414

(S,E)-5-((cyclopropylmethyl)(1- (4-(dimethylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 415

(S,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 416

(S,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 417

(S,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl)piperidin- 3-yl)amino)-[3,4′-bipyridin]-6(1H)-one 418

(S,E)-5-((cyclopropylmethyl)(1- (4-(isopropylamino)but-2-enoyl) pyrrolidin-3-yl)amino)- 2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 419

(S,E)-5-((cyclopropylmethyl)(1-(4- (isopropylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 420

(S,E)-5-((cyclopropylmethyl) (1-(4-(isopropylamino)but- 2-enoyl)pyrrolidin- 3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 421

(S,E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)piperidin- 3-yl)amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 422

(S,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but-2-enoyl) piperidin-3-yl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 423

(S,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but-2-enoyl) piperidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 424

(S,E)-5-((cyclopropylmethyl) (1-(4-(methylamino)but- 2-enoyl)pyrrolidin- 3-yl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 425

(S,E)-5-((cyclopropylmethyl)(1-(4- (methylamino)but-2-enoyl)pyrrolidin- 3-yl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 426

(S,E)-5-((cyclopropylmethyl)(1- (4-(methylamino)but-2-enoyl) pyrrolidin-3-yl)amino)-[3,4′-bipyridin]- 6(1H)-one 427

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 428

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 429

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 430

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 431

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 432

(S,E)-5-(ethyl(1-(4-(isopropylamino) but-2-enoyl)pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 433

(S,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 434

(S,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)- 2′-methoxy-[3,4′-bipyridin]-6(1H)- one 435

(S,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)piperidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 436

(S,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)pyrrolidin-3-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 437

(S,E)-5-(ethyl(1-(4-(methylamino)but- 2-enoyl)pyrrolidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]- 6(1H)-one 438

(S,E)-5-(ethyl(1-(4-(methylamino) but-2-enoyl)pyrrolidin-3-yl)amino)- [3,4′-bipyridin]-6(1H)-one 439

(Z)-4,4-dimethyl-2-(3-((6-oxo-1,6- dihydro-[3,4′-bipyridin]-5-yl)amino) azetidine-1-carbonyl)pent-2-enenitrile 440

2-(3-((2′-(methylamino)-6-oxo- 1,6-dihydro-[3,4′-bipyrindin]-5- yl)amino)azetidine-1-carbonyl) acrylonitrile 441

2-(3-((6-oxo-1,6-dihydro-[3,4′- bipyrindin]-5-yl)amino)azetidine- 1-carbonyl)acrylonitrile 442

3-((1-acryloylazetidin- 3-yl)(cyclopropyl)amino)- 5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 443

3-((1-acryloylazetidin- 3-yl)(cyclopropyl)amino)- 5-(2-methoxypyrimidin- 4-yl)pyridin-2(1H)-one 444

3-((1-acryloylazetidin- 3-yl)(cyclopropyl)amino)- 5-(2-methylpyrimidin-4-yl) pyridin-2(1H)-one 445

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 446

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5-(6- (methylamino)pyrazin-2-yl) pyridin-2(1H)-one 447

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (6-methoxypyrazin-2-yl) pyridin-2(1H)-one 448

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 449

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (6-methylpyrazin-2-yl)pyridin- 2(1H)-one 450

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (6-methylpyrimidin-4-yl)pyridin- 2(1H)-one 451

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (pyrazin-2-yl)pyridin-2(1H)-one 452

3-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-5- (pyrimidin-4-yl)pyridin- 2(1H)-one 453

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- 5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 454

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (2-methoxypyrimidin-4-yl)pyridin- 2(1H)-one 455

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (2-methylpyrimidin-4-yl)pyridin- 2(1H)-one 456

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5-(6- (methylamino)pyrimidin-4-yl)pyridin- 2(1H)-one 457

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (6-(methylamino)pyrazin-2-yl) pyridin-2(1H)-one 458

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (6-methoxypyrimidin-4-yl)pyridin- 2(1H)-one 459

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (6-methoxypyrazin-2-yl)pyridin- 2(1H)-one 460

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (6-methylpyrimidin-4-yl)pyridin- 2(1H)-one 461

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (6-methylpyrazin-2-yl)pyridin- 2(1H)-one 462

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (pyrazin-2-yl)pyridin-2(1H)-one 463

3-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-5- (pyrimidin-4-yl)pyridin-2(1H)-one 464

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 465

3-((1-acryloylazetidin-3-yl) (ethyl)amino)-5-(2- methoxypyrimidin-4-yl) pyridin-2(1H)-one 466

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(2-methylpyrimidin-4-yl) pyridin-2(1H)-one 467

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 468

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 469

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-methoxypyrazin-2-yl) pyridin-2(1H)-one 470

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 471

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-methoxypyrazin-2-yl) pyridin-2(1H)-one 472

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(6-methylpyrimidin-4-yl) pyridin-2(1H)-one 473

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 474

3-((1-acryloylazetidin-3-yl)(ethyl) amino)-5-(pyrimidin-4-yl)pyridin- 2(1H)-one 475

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 476

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(2-methoxypyrimidin-4-yl) pyridin-2(1H)-one 477

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(2-methylpyrimidin-4-yl) pyridin-2(1H)-one 478

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 479

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 480

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-methoxypyrazin-2-yl) pyridin-2(1H)-one 481

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 482

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-methylpyrazin-2-yl) pyridin-2(1H)-one 483

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(6-methylpyrimidin-4-yl) pyridin-2(1H)-one 484

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 485

3-((1-acryloylazetidin-3-yl)(methyl) amino)-5-(pyrimidin-4-yl)pyridin- 2(1H)-one 486

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(2-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 487

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(2-methoxypyrimidin-4-yl) pyridin-2(1H)-one 488

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(2-methylpyrimidin-4-yl) pyridin-2(1H)-one 489

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-(methylamino)pyrazin- 2-yl)pyridin-2(1H)-one 490

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-(methylamino)pyrimidin- 4-yl)pyridin-2(1H)-one 491

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-methoxypyrazin-2-yl) pyridin-2(1H)-one 492

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-methoxypyrimidin-4-yl) pyridin-2(1H)-one 493

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-methylpyrazin-2-yl) pyridin-2(1H)-one 494

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(6-methylpyrimidin-4-yl) pyridin-2(1H)-one 495

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(pyrazin-2-yl)pyridin- 2(1H)-one 496

3-((1-acryloylazetidin-3-yl)(propyl) amino)-5-(pyrimidin-4-yl)pyridin- 2(1H)-one 497

3-((1-acryloylazetidin-3-yl)amino)- 5-(2-methoxypyrimidin-4-yl)pyridin- 2(1H)-one 498

3-((1-acryloylazetidin-3-yl)amino)- 5-(2-methylpyrimidin-4-yl)pyridin- 2(1H)-one 499

3-((1-acryloylazetidin-3-yl)amino)- 5-(6-(methylamino)pyrimidin-4-yl) pyridin-2(1H)-one 500

3-((1-acryloylazetidin-3-yl)amino)- 5-(6-methoxypyrimidin-4-yl)pyridin- 2(1H)-one 501

3-((1-acryloylazetidin-3-yl)amino)- 5-(6-methylpyrazin-2-yl)pyridin- 2(1H)-one 502

3-((1-acryloylazetidin-3-yl)amino)- 5-(6-methylpyrimidin-4-yl)pyridin- 2(1H)-one 503

3-((1-acryloylazetidin-3-yl)amino)- 5-(pyrazin-2-yl)pyridin-2(1H)-one 504

3-((1-acryloylazetidin-3-yl)amino)- 5-(pyrimidin-4-yl)pyridin-2(1H)-one 505

3-(5-((1-(2-chloroacetyl)azetidin- 3-yl)amino)-6-oxo-1,6-dihydropyridin- 3-yl)-N-(4-isopropyl-3- methylphenyl)benzamide 506

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-N-(4- isopropyl-3-methylphenyl)-5- methylbenzamide 507

3-(5-((1-acryloylazetidin-3-yl) amino)-6-oxo-1,6-dihydropyridin- 3-yl)-5-ethyl-N-(4-isopropyl- 3-methylphenyl)benzamide 508

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-5- isopropyl-N-(4-isopropyl-3- methylphenyl)benzamide 509

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-N- (4-isopropyl-3-methylphenyl)-5- propylbenzamide 510

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-5- cyclopropyl-N-(4-isopropyl-3- methylphenyl)benzamide 511

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-5- cyano-N-(4-isopropyl-3- methylphenyl)benzamide 512

3-(5-((1-acryloylazetidin-3-yl)amino)- 6-oxo-1,6-dihydropyridin-3-yl)-N- (4-isopropyl-3- methylphenyl)benzamide 513

5′-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-[2,3′- bipyridin]-6′(1′H)-one 514

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-[3,4′- bipyridin]-6(1H)-one 515

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-[3,4′- bipyridine]-2′,6(1H,1′H)-dione 516

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-1′-methyl- [3,4′-bipyridine]-2′,6(1H,1′H)-dione 517

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 518

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-2′-methoxy- [3,4′-bipyridin]-6(1H)-one 519

5-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-2′-methyl- [3,4′-bipyridin]-6(1H)-one 520

5′-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 521

5′-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-4-methoxy- [2,3′-bipyridin]-6′(1′H)-one 522

5′-((1-acryloylazetidin-3-yl) (cyclopropyl)amino)-4-methyl- [2,3′-bipyridin]-6′(1′H)-one 523

5′-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)-amino)- [2,3′-bipyridin]-6′(1′H)-one 524

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- [3,4′-bipyridine]-2′,6(1H,1′H)-dione 525

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- [3,4′-bipyridin]-6(1H)-one 526

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-1′-methyl- [3,4′-bipyridine]-2′,6(1H,1′H)-dione 527

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-2′- (methylamino)-[3,4′-bipyridin]- 6(1H)-one 528

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- 2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 529

5-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-2′-methyl- [3,4′-bipyridin]-6(1H)-one 530

5′-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)-4- (methylamino)-[2,3′-bipyridin]- 6′(1′H)-one 531

5′-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- 4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 532

5′-((1-acryloylazetidin-3-yl) (cyclopropylmethyl)amino)- 4-methyl-[2,3′-bipyridin]-6′(1′H)-one 533

5′-((1-acryloylazetidin-3-yl) (ethyl)amino)-[2,3′-bipyridin]- 6′(1′H)-one 534

5-((1-acryloylazetidin-3-yl) (ethyl)amino)-[3,4′-bipyridin]- 6(1H)-one 535

5-((1-acryloylazetidin-3-yl) (ethyl)amino)-[3,4′-bipyridine]- 2′,6(1H,1′H)-dione 536

5-((1-acryloylazetidin-3-yl) (ethyl)amino)-1′-methyl-[3,4′- bipyridine]-2′,6(1H,1′H)-dione 537

5-((1-acryloylazetidin-3-yl)(ethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 538

5-((1-acryloylazetidin-3-yl)(ethyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 539

5-((1-acryloylazetidin-3-yl)(ethyl) amino)-2′-methyl-[3,4′-bipyridin]- 6(1H)-one 540

5′-((1-acryloylazetidin-3-yl)(ethyl) amino)-4-(methylamino)-[2,3′- bipyridin]-6′(1′H)-one 541

5′-((1-acryloylazetidin-3-yl)(ethyl) amino)-4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 542

5′-((1-acryloylazetidin-3-yl)(ethyl) amino)-4-methyl-[2,3′-bipyridin]- 6′(1′H)-one 543

5′-((1-acryloylazetidin-3-yl) (methyl)amino)-[2,3′-bipyridin]- 6′(1′H)-one 544

5-((1-acryloylazetidin-3-yl) (methyl)amino)-[3,4′-bipyridin]- 6(1H)-one 545

5-((1-acryloylazetidin-3-yl) (methyl)amino)-[3,4′-bipyridine]- 2′,6(1H,1′H)-dione 546

5-((1-acryloylazetidin-3-yl)(methyl) amino)-1′-methyl-[3,4′-bipyridine]- 2′,6(1H,1′H)-dione 547

5-((1-acryloylazetidin-3-yl) (methyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 548

5-((1-acryloylazetidin-3-yl) (methyl)amino)-2′-methoxy-[3,4′- bipyridin]-6(1H)-one 549

5-((1-acryloylazetidin-3-yl)(methyl) amino)-2′-methyl-[3,4′-bipyridin]- 6(1H)-one 550

5′-((1-acryloylazetidin-3-yl) (methyl)amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 551

5′-((1-acryloylazetidin-3-yl)(methyl) amino)-4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 552

5′-((1-acryloylazetidin-3-yl)(methyl) amino)-4-methyl-[2,3′-bipyridin]- 6′(1′H)-one 553

5′-((1-acryloylazetidin-3-yl)(propyl) amino)-[2,3′-bipyridin]-6′(1′H)-one 554

5-((1-acryloylazetidin-3-yl)(propyl) amino)-[3,4′-bipyridin]-6(1H)-one 555

5-((1-acryloylazetidin-3-yl)(propyl) amino)-[3,4′-bipyridine]-2′,6(1H,1′H)- dione 556

5-((1-acryloylazetidin-3-yl)(propyl) amino)-1′-methyl-[3,4′-bipyridine]- 2′,6(1H,1′H)-dione 557

5-((1-acryloylazetidin-3-yl) (propyl)amino)-2′-(methylamino)- [3,4′-bipyridin]-6(1H)-one 558

5-((1-acryloylazetidin-3-yl)(propyl) amino)-2′-methoxy-[3,4′-bipyridin]- 6(1H)-one 559

5-((1-acryloylazetidin-3-yl)(propyl) amino)-2′-methyl-[3,4′-bipyridin]- 6(1H)-one 560

5′-((1-acryloylazetidin-3-yl)(propyl) amino)-4-(methylamino)- [2,3′-bipyridin]-6′(1′H)-one 561

5′-((1-acryloylazetidin-3-yl)(propyl) amino)-4-methoxy-[2,3′-bipyridin]- 6′(1′H)-one 562

5′-((1-acryloylazetidin-3-yl)(propyl) amino)-4-methyl-[2,3′-bipyridin]- 6′(1′H)-one 563

5′-((1-acryloylazetidin-3-yl)amino)- [2,3′-bipyridin]-6′(1′H)-one 564

5-((1-acryloylazetidin-3-yl)amino)- [3,4′-bipyridine]-2′,6(1H,1′H)-dione 565

5-((1-acryloylazetidin-3-yl) amino)-1′-methyl-[3,4′- bipyridine]-2′,6(1H,1′H)-dione 566

5-((1-acryloylazetidin-3-yl)amino)-2′- methoxy-[3,4′-bipyridin]-6(1H)-one 567

5′-((1-acryloylazetidin-3-yl)amino)-4- (methylamino)-[2,3′-bipyridin]- 6′(1′H)-one 568

5′-((1-acryloylazetidin-3-yl)amino)- 4-methoxy-[2,3′-bipyridin]-6′(1′H)-one 569

5′-((1-acryloylazetidin-3-yl)amino)- 4-methyl-[2,3′-bipyridin]-6′(1′H)-one 570

5-((1-acryloylpiperidin-4-yl) (cyclopropylmethyl)amino)- [3,4′-bipyridin]-6(1H)-one 571

5-((1-acryloylpiperidin-4-yl) (cyclopropylmethyl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 572

5-((1-acryloylpiperidin-4-yl)(ethyl) amino)-[3,4′-bipyridin]-6(1H)-one 573

5-((1-acryloylpiperidin-4-yl)(ethyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 574

5-((1-acryloylpiperidin-4-yl)(methyl) amino)-[3,4′-bipyridin]-6(1H)-one 575

5-((1-acryloylpiperidin-4-yl)(methyl) amino)-2′-(methylamino)-[3,4′- bipyridin]-6(1H)-one 576

5-((1-acryloylpiperidin-4-yl)amino)- [3,4′-bipyridin]-6(1H)-one 577

5-((1-acryloylpiperidin-4-yl)amino)- 2′-(methylamino)-[3,4′-bipyridin]- 6(1H)-one 578

O═C1C(N(C)C2CN(C(/ C═C/CNC(C)C)═O)C2) ═CC(C3═CC═NC═N3)═CN1 Example Smiles 1 O═C1C(N[C @ @ H]2CCCN(C(CCl)═O)C2)═CC(C3═CC═NC═C3)═CN1 2 O═C1C(N[C @ @ H]2CCCN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 3 O═C1C(N[C @ @ H]2CCN(C(C═C)═O)C2)═CC═(C3═CC═NC═C3)═CN1 4 O═C1C(NC2CN(C(CCl)═O)C2)═CC(C3═CC═NC═C3)═CN1 5 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 6 O═C1C(NC2CN(C(/C═C/C)═O)C2)═CC(C3═CC═NC═C3)═CN1 7 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═C3)═CN1 8 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 9 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 10 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 11 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 12 O═C1C(NC2CN(C(/C═C/C(NC)═O)═O)C2)═CC(C3═CC═NC═C3)═CN1 13 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC═NC═C3)═CN1 14 O═C1C(NC2CN(C(/C═C/C3═CC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 15 O═C1C(NC2CN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 16 17 18 O═C1C(NC2CN(C(/C═C/CC)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 19 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 20 O═C1C(NC2CN(C(/C═C/CCOC3═CC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 21 O═C1C(NC2CN(C(/C(C#N)═C/C)═O)C2)═CC(C3═CC═NC(NC)═C3)═CN1 22 O═C1C(NC2CN(C(/C(C#N)═C/C)═O)C2)═CC(C3═CC═NC═C3)═CN1 23 O═C1C(NC2CN(C(/C═C/C3═CC═CC═N3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 24 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 25 O═C1C(NC2CCN(C(/C═C/CNC)═O)CC2═CC(C3═CC(NC)═NC═C3)═CN1 26 O═C1C(NC2CN(C(/C═C/CN3CCCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 27 O═C1C(NC2CN(C(/C═C/CC3═NC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 28 O═C1C(NC2CN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 29 O═C1C(NC2CN(C(/C═C/CC3CCOCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 30 O═C1C(NC2CN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 31 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 32 O═C1C(NC2CCN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 33 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 34 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 35 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 36 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(NC)═NC═C3═CN1 37 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 38 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 39 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC═CN═C3)═CN1 40 O═C1C(N(C)C2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC═NC═C3)═CN1 41 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 42 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 43 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 44 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 45 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 46 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 47 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC═CN═C3)═CN1 48 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═NC═NC═C3)═CN1 49 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 50 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 51 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 52 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 53 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 54 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 55 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC═CN═C3)═CN1 56 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC═NC═C3)═CN1 57 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 58 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 59 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 60 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 61 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 62 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 63 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC═CN═C3)═CN1 64 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═NC═NC═C3)═CN1 65 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 66 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 67 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 68 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC═CN═C3)═CN1 69 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC═NC═C3)═CN1 70 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 71 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 72 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 73 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3═CC(C4═NC(NC)═NC═C4)═CN1 74 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 75 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 76 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═NC═CN═C4)═CN1 77 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═NC═NC═C4)═CN1 78 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 79 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 80 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 81 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 82 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 83 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 84 O═C1C(N(C)C2CN(C(/C═C/CN═O)C2)═CC(C3═NC═CN═C3)═CN1 85 O═C1C(N(C)C2CN(C(/C═C/CN)═O)C2)═CC(C3═NC═NC═C3)═CN1 86 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 87 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 88 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 89 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 90 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 91 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 92 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC═CN═C3)═CN1 93 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═NC═NC═C3)═CN1 94 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 95 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 96 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 97 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC(NC)═NC═C4)═CN1 98 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 99 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 100 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC═CN═C4)═CN1 101 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═NC═NC═C4)═CN1 102 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 103 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 104 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 105 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC(NC)═NC═C4)═CN1 106 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 107 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 108 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC═CN═C4)═CN1 109 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═NC═NC═C4)═CN1 110 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 111 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 112 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 113 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC(NC)═NC═C4)═CN1 114 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 115 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 116 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC═CN═C4)═CN1 117 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═NC═NC═C4)═CN1 118 O═C(NC1═CC(C)═C(C(C)C)C═C1)═C2═CC(C3═CNC(C(NC4CN(C(/C═C/CN(C)C)═O)C4)═C3)═O)═CC(C)═C2 119 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(C(NC4═CC(C)═C(C(C)C)C═C4)═O)═CC═C3)═CN1 120 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 121 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 122 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 123 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC═CN═C3)═CN1 124 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC═NC═C3)═CN1 125 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(/C═C/CN(C)C)═O)C4)═C3)═O═CC(C#N)═C2 126 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 127 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 128 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC═CC═N3)═CN1 129 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC═NC═C3)═CN1 130 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 131 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 132 O═C1C(NC2CN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 133 O═C1C(N(CC)C2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 134 O═C1C(N(CC)C2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 135 O═C1C(N(CC)C2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 136 O═C1C(NC2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 137 O═C1C(NC2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 138 O═C1C(NC2CCN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 139 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC═CC═N3)═CN1 140 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC═NC═C3)═CN1 141 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 142 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 143 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 144 O═C1C(NC2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 145 O═C1C(NC2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 146 O═C1C(NC2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 147 O═C1C(NC2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 148 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC═CC═N3)═CN1 149 O═C1C(NC2CCN(C(/C═C/CNC)═O)CC2)═CC(C3═CC═NC═C3)═CN1 150 O═C1C(NC2CN(C(/C═C/CN3CCCCC3)═O)C2═CC(C4═CC═NC═C4)═CN1 151 O═C1C(NC2CN(C(/C═C/CC3═NC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 152 O═C1C(NC2CN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 153 O═C1C(NC2CN(C(/C═C/CC3CCOCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 154 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 155 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 156 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC═CC═N4)═CN1 157 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 158 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 159 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN)═O)C3)═CC(C4═CC═NC═C4)═CN1 160 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC═CC═N3)═CN1 161 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC═NC═C3)═CN1 162 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 163 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 164 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 165 O═C1C(NC2CN(C(/C═C/CN)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 166 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 167 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 168 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN)═O)CC3)═CC(C4═CC═NC═C4)═CN1 169 O═C1C(N(CC)C2CCN(C(/C═C/CN)═O)CC2)═CC(C3═CC═NC═C3)═CN1 170 O═C1C(N(CC)C2CCN(C(/C═C/CN)═O)CC2)CC(C3═CC(NC)═NC═C3)═CN1 171 O═C1C(N(CC)C2CCN(C(/C═C/CN)═O)CC2)CC(C3═CC(OC)═NC═C3)═CN1 172 O═C1C(NC2CCN(C(/C═C/CN)═O)CC2)CC(C3═CC═NC═C3)═CN1 173 O═C1C(NC2CCN(C(/C═C/CN)═O)CC2)CC(C3═CC(NC)═NC═C3)═CN1 174 O═C1C(NC2CCN(C(/C═C/CN)═O)CC2)CC(C3═CC(OC)═NC═C3)═CN1 175 O═C1C(NC2CN(C(/C═C/CC3CCCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 176 O═C1C(NC2CN(C(/C═C/CC3CCCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 177 O═C1C(NC2CN(C(/C═C/COC(C)C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 178 O═C1C(NC2CN(C(/C═C/COC)═O)C2)═CC(C3═CC═NC═C3)═CN1 179 O═C1C(NC2CN(C(/C═C/COC)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 180 O═C1C(NC2CN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 181 O═C1C(NC2CN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 182 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 183 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 184 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC═CC═N4)═CN1 185 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 186 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 187 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC═NC═C4)═CN1 188 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 189 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 190 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 191 O═C1C(N(CC2CC2)C3CN(C(/C═C/CN(C)C)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 192 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 193 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC═CC═N4)═CN1 194 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 195 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 196 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC(C)C)═O)C3)═CC(C4═CC═NC═C4)═CN1 197 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 198 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 199 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 200 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 201 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 202 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC═CC═N4)═CN1 203 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 204 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 205 O═C1C(N(CC2CC2)C3CN(C(/C═C/CNC)═O)C3)═CC(C4═CC═NC═C4)═CN1 206 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 207 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 208 O═C1C(N(CC2CC2)C3CCN(C(/C═C/CNC)═O)CC3)═CC(C4═CC═NC═C4)═CN1 209 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 210 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 211 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 212 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 213 O═C1C(NC2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 214 O═C1C(N(C)C2CN(C(/C═C/CNC)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 215 O═C1C(N(CC)C2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 216 O═C1C(N(CC)C2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 217 O═C1C(N(CC)C2CCN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 218 O═C1C(N(CC)C2CCN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 219 O═C1C(N(CC)C2CCN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 220 O═C1C(N(CC)C2CCN(C(/C═C/CNC)═O)CC2)═CC(C3═CC═NC═C3)═CN1 221 O═C1C(N[C @ @ H]2CCCN(C(CCl)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 222 O═C1C(N[C @ @ H]2CCN(C(CCl)═O)C2)═CC(C3═CC═NC═C3)═CN1 223 O═C1C(N[C @ @ H]2CCN(C(CCl)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 224 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 225 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 226 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 227 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 228 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 229 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 230 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 231 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 232 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1•C 233 O═C1C(N[C @ @ H]2CCCN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 234 O═C1C(N[C @ @ H]2CCCN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 235 O═C1C(N[C @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 236 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 237 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 238 O═C1C(N(CC2CC2)[C @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 239 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 240 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 241 O═C1C(N(CC)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 242 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 243 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 244 O═C1C(N(C)[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 245 O═C1C(N[C @ @ H]2CCN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 246 O═C1C(N[C @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 247 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 248 O═C1C(N[C @ @ H]2CCN(C(/C═C/CNC)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 249 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN3CCCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 250 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 251 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CC3═NC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 252 O═C1C(N[C @ @ H]2CCN(C(/C═C/CC3═NC═CC═C3═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 253 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 254 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 255 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 256 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 257 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 258 O═C1C(N[C @ @ H]2CCN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC(NC)═NC═C4)═CN1 259 O═C1C(N[C @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 260 O═C1C(N[C @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 261 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 262 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 263 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 264 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC═NC═C3)═CN1 265 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 266 O═C1C(N[C @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 267 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 268 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 269 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 270 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 271 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN(C)C)═O)C2)═CC(C3═CC═NC═C3)═CN1 272 O═C1C(N[C @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 273 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 274 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 275 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 276 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 277 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 278 O═C1C(N[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 279 O═C1C(N[C @ H]2CCCN(C(/C═C/CNC)═O)C2)═CC(C3═CC═NC═C3)═CN1 280 O═C1C(N[C @ @ H]2CCN(C(/C═C/CNC)═O)C2)═CC(C3═CC═NC═C3)═CN1 281 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 282 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 283 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CC3═NC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 284 O═C1C(N[C @ @ H]2CCN(C(/C═C/CC3═NC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 285 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 286 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 287 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 288 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 289 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 290 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 291 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 292 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 293 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN)═O)C2)═CC(C3═CC═NC═C3)═CN1 294 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 295 O═C1C(N[C @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 296 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 297 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 298 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC═NC═C4)═CN1 299 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC═NC═C3)═CN1 300 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 301 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 302 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN)═O)C2)═CC(C3═CC═NC═C3)═CN1 303 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 304 O═C1C(N[C @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 305 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 306 O═C1C(N[C @ @ H]2CCN(C(/C═C/CN3CCOCC3)═O)C2)═CC(C4═CC═NC═C4)═CN1 307 O═C1C(N[C @ @ H]2CCCN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 308 O═C1C(N[C @ @ H]2CCN(C(/C═C/CC3═CC═CC═C3)═O)C2)═CC(C4═CC═NC═C4)═CN1 309 O═C1C(N[C @ @ H]2CCCN(C(/C═C/C)═O)C2)═CC(C3═CC═NC═C3)═CN1 310 O═C1C(N[C @ @ H]2CCCN(C(/C═C/C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 311 O═C1C(N[C @ @ H]2CCN(C(/C═C/C)═O)C2)═CC(C3═CC═NC═C3)═CN1 312 O═C1C(N[C @ @ H]2CCN(C(/C═C/C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 313 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 314 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 315 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 316 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 317 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 318 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 319 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 320 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 321 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 322 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 323 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 324 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 325 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 326 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 327 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 328 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 329 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 330 O═C1C(N(CC2CC2)[C @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC═NC═C4)═CN1 331 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 332 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 333 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 334 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 335 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 336 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 337 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 338 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 339 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 340 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 341 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 342 O═C1C(N(CC)[C @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC═NC═C3)═CN1 343 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 344 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 345 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 346 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 347 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 348 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 349 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 350 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 351 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 352 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 353 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 354 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 355 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 356 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 357 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(C═C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 358 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 359 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 360 O═C1C(N(CC)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 361 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 362 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 363 O═C1C(N(C)[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 364 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 365 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 366 O═C1C(N[C @ @ H]2CN(C(C═C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 367 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 368 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 369 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 370 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 371 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 372 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 373 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 374 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 375 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 376 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 377 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 378 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 379 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 380 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 381 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 382 O═C1C(N[C @ @ H]2CN(C(/C═C/CN(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 383 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 384 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 385 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 386 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 387 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 388 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 389 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 390 O═C1C(N[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC═NC═C3)═CN1 391 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 392 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 393 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 394 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 395 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 396 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 397 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 398 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 399 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 400 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 401 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 402 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN)═O)CC3)═CC(C4═CC═NC═C4)═CN1 403 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC═NC═C3)═CN1 404 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 405 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 406 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC═NC═C3)═CN1 407 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 408 O═C1C(N[C @ @ H]2CN(C(/C═C/CN)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 409 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 410 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 411 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 412 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 413 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 414 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CN(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 415 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 416 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 417 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 418 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 419 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 420 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC(C)C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 421 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC(NC)═NC═C4)═CN1 422 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC(OC)═NC═C4)═CN1 423 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CCC3)═CC(C4═CC═NC═C4)═CN1 424 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 425 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC(OC)═NC═C4)═CN1 426 O═C1C(N(CC2CC2)[C @ @ H]3CN(C(/C═C/CNC)═O)CC3)═CC(C4═CC═NC═C4)═CN1 427 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 428 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 429 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 430 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 431 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 432 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC(C)C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 433 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(NC)═NC═C3)═CN1 434 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC(OC)═NC═C3)═CN1 435 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CCC2)═CC(C3═CC═NC═C3)═CN1 436 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 437 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC(OC)═NC═C3)═CN1 438 O═C1C(N(CC)[C @ @ H]2CN(C(/C═C/CNC)═O)CC2)═CC(C3═CC═NC═C3)═CN1 439 O═C1C(NC2CN(C(/C(C#N)═C/C(C)(C)C)═O)C2)═CC(C3═CC═NC═C3)═CN1 440 O═C1C(NC2CN(C(C(C#N)═C═O)C2)═CC(C3═CC═NC(NC)═C3)═CN1 441 O═C1C(NC2CN(C(C(C#N)═C═O)C2)═CC(C3═CC═NC═C3)═CN1 442 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(NC)═NC═C4)═CN1 443 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 444 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(C)═NC═C4)═CN1 445 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 446 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 447 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 448 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 449 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(C)═CN═C4)═CN1 450 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═NC═N4)═CN1 451 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC═CN═C4)═CN1 452 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC═NC═C4)═CN1 453 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(NC)═NC═C4)═CN1 454 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(OC)═NC═C4)═CN1 455 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(C)═NC═C4)═CN1 456 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═NC═N4)═CN1 457 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(NC)═CN═C4)═CN1 458 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═NC═N4)═CN1 459 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(OC)═CN═C4)═CN1 460 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═NC═N4)═CN1 461 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC(C)═CN═C4)═CN1 462 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC═CN═C4)═CN1 463 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═NC═NC═C4)═CN1 464 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 465 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 466 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═NC═C3)═CN1 467 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 468 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 469 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 470 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 471 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═CN═C3)═CN1 472 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═N3)═CN1 473 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC═CN═C3)═CN1 474 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═NC═NC═C3)═CN1 475 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 476 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 477 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═NC═C3)═CN1 478 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 479 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 480 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 481 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 482 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═CN═C3)═CN1 483 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═N3)═CN1 484 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC═CN═C3)═CN1 485 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═NC═NC═C3)═CN1 486 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═NC═C3)═CN1 487 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 488 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═NC═C3)═CN1 489 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(NC)═CN═C3)═CN1 490 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 491 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═CN═C3)═CN1 492 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 493 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC(C)═CN═C3)═CN1 494 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═N3)═CN1 495 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC═CN═C3)═CN1 496 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═NC═NC═C3)═CN1 497 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(OC)═NC═C3)═CN1 498 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(C)═NC═C3)═CN1 499 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═N3)═CN1 500 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═N3)═CN1 501 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC(C)═CN═C3)═CN1 502 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═N3)═CN1 503 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC═CN═C3)═CN1 504 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═NC═NC═C3)═CN1 505 O═C1C(NC2CN(C(CCl)═O)C2)═CC(C3═CC(C(NC4═CC(C)═C(C(C)C)C═C4)═O)═CC═C3)═CN1 506 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(C)═C2 507 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(CC)═C2 508 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(C(C)C)═C2 509 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(CCC)═C2 510 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(C5CC5)═C2 511 O═C(NC1═CC(C)═C(C(C)C)C═C1)C2═CC(C3═CNC(C(NC4CN(C(C═C)═O)C4)═C3)═O)═CC(C#N)═C2 512 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(C(NC4═CC(C)═C(C(C)C)C═C4)═O)═CC═C3)═CN1 513 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC═CC═N4)═CN1 514 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC═NC═C4)═CN1 515 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C(C═CN4)═CC4═O)═CN1 516 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C(C═CN4C)═CC4═O)═CN1 517 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 518 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 519 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═NC═C4)═CN1 520 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 521 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 522 O═C1C(N(C2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═CC═N4)═CN1 523 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC═CC═N4)═CN1 524 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C(C═CN4)═CC4═O)═CN1 525 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC═NC═C4)═CN1 526 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C(C═CN4C)═CC4═O)═CN1 527 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═NC═C4)═CN1 528 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═NC═C4)═CN1 529 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═NC═C4)═CN1 530 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(NC)═CC═N4)═CN1 531 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(OC)═CC═N4)═CN1 532 O═C1C(N(CC2CC2)C3CN(C(C═C)═O)C3)═CC(C4═CC(C)═CC═N4)═CN1 533 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC═CC═N3)═CN1 534 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 535 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C(C═CN3)═CC3═O)═CN1 536 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C(C═CN3C)═CC3═O)═CN1 537 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 538 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 539 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═C3)═CN1 540 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 541 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 542 O═C1C(N(CC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═CC═N3)═CN1 543 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC═CC═N3)═CN1 544 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 545 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C(C═CN3)═CC3═O)═CN1 546 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C(C═CN3C)═CC3═O)═CN1 547 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 548 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 549 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═C3)═CN1 550 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 551 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 552 O═C1C(N(C)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═CC═N3)═CN1 553 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC═CC═N3)═CN1 554 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC═NC═C3)═CN1 555 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C(C═CN3)═O)═CN1 556 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C(C═CN3C)═CC3═O)═CN1 557 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═NC═C3)═CN1 558 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 559 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═NC═C3)═CN1 560 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 561 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 562 O═C1C(N(CCC)C2CN(C(C═C)═O)C2)═CC(C3═CC(C)═CC═N3)═CN1 563 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC═CC═N3)═CN1 564 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C(C═CN3)═CC3═O)═CN1 565 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C(C═CN3C)═CC3═O)═CN1 566 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═NC═C3)═CN1 567 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(NC)═CC═N3)═CN1 568 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(OC)═CC═N3)═CN1 569 O═C1C(NC2CN(C(C═C)═O)C2)═CC(C3═CC(C)═CC═N3)═CN1 570 O═C1C(N(CC2CC2)C3CCN(C(C═C)═O)CC3)═CC(C4═CC═NC═C4)═CN1 571 O═C1C(N(CC2CC2)C3CCN(C(C═C)═O)CC3)═CC(C4═CC(NC)═NC═C4)═CN1 572 O═C1C(N(CC)C2CCN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 573 O═C1C(N(CC)C2CCN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 574 O═C1C(N(C)C2CCN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 575 O═C1C(N(C)C2CCN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 576 O═C1C(NC2CCN(C(C═C)═O)CC2)═CC(C3═CC═NC═C3)═CN1 577 O═C1C(NC2CCN(C(C═C)═O)CC2)═CC(C3═CC(NC)═NC═C3)═CN1 578 O═C1C(N(C)C2CN(C(/C═C/CNC(C)C)═O)C2)═CC(C3═CC═NC═N3)═CN1

Biological Activity Assays

Compounds disclosed herein which are tested in the following assays are expected to be efficacious in the assays.

ITK Inhibitor Binding Potency

The ability of candidate compounds to interact with ITK is quantitated by a competitive binding assay using the LanthaScreen technology developed by Life Technologies. This assay is based on the binding of a proprietary, Alexa Fluor® 647-labeled, ATP-competitive kinase inhibitor (kinase tracer-236) to the ITK expression construct in the presence of a Europium-conjugated antibody, resulting in a FRET (fluorescence resonance energy transfer) signal. Displacement of the kinase tracer by compound results in a lower emission ratio upon excitation of the Europium chelate. Candidate compounds are designed as potential irreversible inhibitors of ITK, capable of ligating to an active site cysteine residue resulting in time dependent covalent binding. The time dependent nature of irreversible inhibition is investigated by performing the binding assay with and without a pre-incubation of compound and ITK. An increase in potency in the pre-incubated assay suggests the candidate compound could be irreversibly modifying ITK or having a slowly reversible mechanism. The inhibitory potency of candidate compounds is measured in 20 mM HEPES pH 7.5, 10 mM MgCl₂, 0.01% BSA, 0.0005% Tween-20, and 2% DMSO in the presence of 10 nM ITK, 2 nM Eu-anti-GST antibody, and 50 nM kinase tracer-236 using a 384-well plate format. Background signal is defined in the absence of ITK and uninhibited signal is defined in the presence of vehicle (2% DMSO) alone. Compounds were evaluated in an 11-point dose-response ranging from 20 uM to 0.34 nM. The binding assays are performed under two preincubation Conditions to evaluate time dependence of inhibition. For the pre-incubation assay, ITK and Eu-anti-GST antibody are pre-incubated with compound or vehicle for two hours prior to the addition of kinase tracer. The non-preincubated assay is run under Conditions where ITK and Eu-anti-GST antibody are added to a mixture of compound and kinase tracer. IC₅₀ values of compounds are determined using a 4 parameter logistical fit of emission ratio as a function of the concentration of compound.

ITK Inhibitor Binding Kinetics

To obtain a better understanding of the kinetics of binding by inhibitor compounds to ITK, association and dissociation experiments were performed. Using the same TR-FRET buffer and Conditions as described above, the kinetic rate constants for the binding of KT-236 to ITK were initially determined. Once knowing the association (k_(on)) and dissociation (k_(off)) rates of KT-236 binding, the binding kinetics for these candidate compounds could be further elucidated. The dissociation rates were determined by pre-incubating ITK for two hours with various concentrations of the candidate compounds. After this period of time, excess (200 nM final) KT-236 was added to the incubation and the resulting increase in fluorescence followed for approximately four hours. For the association rates, ITK was pre-incubated with KT-236 (50 nM) for 90-120 minutes and then various concentrations of candidate compound added. The resulting decrease in signal was then evaluated for the next two hours. Data from both sets of time course experiments was then analyzed using Dynafit software to obtain the kinetic rate constants (k_(on), k_(off), kinact, K_(i)) utilizing multiple reaction models.

ITK Target Modulation Assay

Target modulation was based upon the ability of a compound to inhibit ITK phosphorylation of its substrate, PLCγ1, at Y783. Human Jurkat T cells were placed in snap-cap polypropylene tubes at 4 million per tube in 800 μL medium (RPMI1640 with 10% heat inactivated serum and 12.3 mM 2-mercaptoethanol and supplemented with glutamine/penicillin/streptomycin). Compounds were added as 100 μL of 10× working stock solutions in medium with 1% DMSO (or medium with 1% DMSO for Controls) and placed in a 37° C. incubator for 2 hours. Stimulation was carried out using CD3/CD28 Dynabeads to activate the T cell receptor and mimic antigen-presenting cells. Beads were added for 100 sec at a ratio of 1 bead per cell, in 100 μL medium (or medium alone for unstimulated Control). Starting at 70 sec, cells and beads were pelleted in a microfuge for 15 sec, the supernatant aspirated, and 50 μL lysis buffer was added per tube and mixed with the pellet at the 100 sec time point. Tubes were placed on a rotator for 30 min at 4° C., and cell debris was pelleted in a microfuge. Supernatant was mixed 1:1 with 2× Sample Buffer and subjected to SDS-polyacrylamide gel electrophoresis. After transfer to nitrocellulose, immunoblotting was done with anti-phospho-Y783 PLCγ1 antibody. Immunoblots were visualized with ECL using horseradish peroxidase conjugated secondary antibody.

ITK IL-2 Release Assay

This assay was based on the ability of a compound to inhibit ITK mediated IL-2 release. Jurkat cells were placed in wells of a 96-well plate at 500,000 per well in 120 μL medium (same as above). Compounds were added as 15 μL per well of 10× working stock solutions in medium with 1% DMSO (or medium with 1% DMSO for Controls) and placed in a 37° C. incubator for 2 hours. Stimulation used CD3/CD28 Dynabeads to activate the T cell receptor and mimic antigen-presenting cells. Beads were added at a ratio of 1 bead per cell, in 15 μL medium (or medium alone for unstimulated Control). After overnight incubation, the plates were centrifuged at 290×g for 5 min, then 100 μL per well of supernatant medium removed for IL-2 cytokine assay. To determine cell viability, to the remaining well Contents 50 μL of CellTiter-Glo reagent was added and luminescence determined. The IL-2 cytokine assay utilized an electochemiluminescence-based ELISA.

TABLE 3 Biological Activity ITK Inhibition IC₅₀ uM IL-2 Production Inhibition IC₅₀ uM Example (+ indicates ≦ 1 μM; (+ indicates ≦ 1 μM; # − indicates > 1 μM) − indicates > 1 μM) 1 + 2 − 3 − 4 + 5 + 6 − 7 + 8 + 9 + + 10 + + 11 + + 12 − 13 + 14 − 15 − 16 + 17 − 18 + 19 + 20 +

Other Anti-Inflammatory Assays

Anti-inflammatory Efficacy—Rat Carrageenan Foot Pad Edema: The compounds of the present disclosure will be evaluated for efficacy in vivo in a model of inflammation. Methods to determine efficacy in rat carrageenan footpad edema are described in U.S. Pat. No. 5,760,068.

Male Sprague Dawley rats are selected for equal average body weight per group. After fasting, with free access to water sixteen hours prior to test, animals are dosed orally (1 mL) with test compounds in a vehicle Containing 0.5% methylcellulose and 0.025% surfactant. The Control group is dosed with vehicle alone.

One hour after dosing, a sub plantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline is administered in one foot, to all animals. The volume of the injected foot is measured using a displacement plethysmometer. Foot volume is measured again three hours after carrageenan injection. The three hour foot volume measurement is compared between treated and Control groups; the percent inhibition of edema is calculated.

Anti-inflammatory Efficacy—Rat Carrageenan-Induced Analgesia Test: The compounds of the present disclosure will be evaluated for efficacy in vivo in a model of inflammatory analgesia. Methods to determine efficacy in rat carrageenan-induced analgesia test are described in U.S. Pat. No. 5,760,068.

Male Sprague Dawley rats are selected for equal average body weight per group. After fasting, with free access to water sixteen hours prior to test, animals are dosed orally (1 mL) with test compounds in vehicle Containing 0.5% methylcellulose and 0.025% surfactant. Control groups are dosed with vehicle alone.

One hour after dosing, a sub plantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline is administered in one foot, to all animals. Three hours after carrageenan injection, rats are placed in a plexiglass Container with a high intensity lamp under the floor. After twenty minutes, thermal stimulation is begun on either the injected or the uninjected foot. Foot withdrawal is determined by a photoelectric cell. The time until foot withdrawal is measured and compared between treated and Control groups. The percent inhibition of the hyperalgesic foot withdrawal is calculated.

Efficacy in Collagen-Induced Arthritis: The compounds of the present disclosure will be evaluated in a mouse autoimmune model of rheumatoid arthritis. Methods to determine efficacy in collagen-induced arthritis in the mouse are described by Grimstein, et al. (2011) J. Translational Med. 9, 1-13.

Six-week-old male DBA/1J mice are obtained from The Jackson Laboratory. At eight weeks of age, mice are orally administered test compounds daily. Mice are immunized by intradermal injection, at twelve weeks of age, with 0.1 mL of emulsion Containing 100 μg of bovine type II collagen (bCII). At 21 days following immunization, mice are boosted with 0.1 mL of bCII (100 μg) emulsified in equal volume of incomplete Freund's Adjuvant (IFA) (Difco, Detroit, Mich.). All mice are monitored three times for the incidence of arthritis and evaluation of a clinical score, ranging from 0-4 was used (0: no swelling or redness; 1: detectable arthritis with erythema; 2: significant swelling and redness; 3: severe swelling and redness from joint to digit; 4: joint stiffness or deformity with ankylosis). The score is calculated from the average cumulative value of all four paws. Severe arthritis is defined as a score >3.

For terminal evaluation of arthritis, mice are euthanized 28 days after initial immunization. The two hind limbs are removed, fixed in formalin, decalcified in RDO solution (Apex Engineering, Aurora, Ill.) for 10-20 min depending on tissue size and examined for pliability. Sections are cut (4 μm thick) and stained with hematoxylin and eosin. Histological evaluation is performed by examining for infiltration of immune cells, hyperplasia, pannus formation and bone deformation for each paw, using a scale ranging from 0-3, according to severity of pathological changes (0: normal, 1: mild, 2: moderate, 3: severe).

Other Embodiments

The detailed description set-forth above is provided to aid those skilled in the art in practicing the present disclosure. However, the disclosure described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed because these embodiments are intended as illustration of several aspects of the disclosure. Any equivalent embodiments are intended to be within the scope of this disclosure. Indeed, various modifications of the disclosure in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description, which do not depart from the spirit or scope of the present inventive discovery. Such modifications are also intended to fall within the scope of the appended claims.

All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art relevant to patentability. Applicant reserves the right to challenge the accuracy and pertinence of the cited references. 

1. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, of Formula (I):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; X is chosen from N and CR³; m is chosen from 1, 2 and 3; and n is chosen from 0, 1, 2, and
 3. 2. A compound of claim 1, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; X is chosen from N or CR³; m is chosen from 1, and 2; and n is chosen from 0, 1, and
 2. 3. A compound of claim 1, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; X is CR³; m is 1; and n is chosen from 0, 1, and
 2. 4. A compound of claim 1, wherein the compound has formula (II):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; X is chosen from N and CR³; and m is chosen from 1, 2 and
 3. 5. A compound of claim 4, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; X is chosen from N and CR³; and m is chosen from 1 and
 2. 6. A compound of claim 4, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; X is CR³; and m is
 1. 7. A compound of claim 1, wherein the compound has formula (III):

wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, C(O)(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, —(CH₂)_(n)C₃₋₇ cycloalkyl, C(O)NHaryl, and C(O)NHheteroaryl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₁₋₄alkyl-O-aryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl, wherein each aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and
 3. 8. A compound of claim 7, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is chosen from hydrogen, halo and C₁₋₄ alkyl; R³ is chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is chosen from cyano, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, C₁₋₄ alkylamino, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NHR⁵, C(O)C₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄alkylaryl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, and CF₃; and m is chosen from 1 and
 2. 9. A compound of claim 7, wherein: Ar is chosen from aryl and heteroaryl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is hydrogen; R³ is hydrogen; R⁴ is chosen from, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CH═CHCH₂R⁸, C(O)C(CN)═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, and (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, and NHC₁₋₄ alkyl; each R⁷ is independently chosen from hydrogen, CN, and C₁₋₄ alkyl; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, OC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, and N(C₁₋₄ alkyl)₂; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, and CF₃; and m is
 1. 10. A compound according to claim 1, which is a compound selected from the group consisting of: 5-((1-(2-chloroacetyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; (E)-5-((1-(but-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-2′-methyl-[3,4′-bipyridin]-6(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(6-methoxypyrazin-2-yl)pyridin-2(1H)-one; 5-((1-acryloylazetidin-3-yl)amino)-2′-(methylamino)-[3,4′-bipyridin]-6(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(2-(methylamino)pyrimidin-4-yl)pyridin-2(1H)-one; 3-((1-acryloylazetidin-3-yl)amino)-5-(6-(methylamino)pyrazin-2-yl)pyridin-2(1H)-one; (E)-N-methyl-4-oxo-4-(3-((6-oxo-1,6-dihydro-[3,4′-bipyridin]-5-yl)amino)azetidin-1-yl)but-2-enamide; and (E)-5-((1-(4-(methylamino)but-2-enoyl)azetidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one.
 11. A compound of claim 7, wherein: Ar is phenyl, 3-methoxyphenyl, 3-aminomethylphenyl, 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl, wherein Ar may be optionally substituted with one or more R⁶ substituents; R² is independently chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and
 3. 12. A compound of claim 7, wherein: Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is independently chosen from hydrogen, halo and C₁₋₄ alkyl; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is chosen from hydrogen, —(CH₂)_(n)C₃₋₇ cycloalkyl, and C₁₋₄ alkyl; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and
 3. 13. A compound of claim 7, wherein: Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from cyano, C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, S(O)₂CH═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, (CH₂)_(m)CR⁷═CR⁹C(O)N(R⁷)₂, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1, 2 and
 3. 14. A compound of claim 7, wherein: Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from C(O)CH₂R², C(O)CF₃, C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1 and
 2. 15. A compound of claim 7, wherein: Ar is 4-pyridine, 3-methyl-4-pyridyl, 3-aminomethyl-4-pyridinyl, 3-aminomethyl-2,4-pyrimidinyl, 3-methoxy-2,5-pyrazinyl, 3-methylamino-2,5-pyrazinyl; R² is hydrogen; R⁴ is independently chosen from C(O)CH═CH₂, C(O)CR⁷═CH₂, C(O)CH═CHR⁷, C(O)CR⁷═CHR⁷, C(O)CH═CR⁷R⁷, C(O)CH═CHCH₂R⁸, C(O)CH═CHCOR⁸, C(O)CH═CHC(O)CH₂R⁸, C(O)C(CN)═CH₂, CO(C(O)NH₂)C═CH₂, (CH₂)_(m)CR⁷═CR⁹C(O)Me, (CH₂)_(m)CR⁷═CR⁹C(O)NH₂, (CH₂)_(m)CR⁷═CR⁹C(O)NHR⁷, and (CH₂)_(m)CR⁷═CR⁹CN; R⁵ is hydrogen; each R⁶ is independently chosen from hydrogen, C₁₋₄ alkyl, OC₁₋₄ alkyl, —(CH₂)_(n)C₃₋₇ cycloalkyl, C₁₋₄ alkylamino, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, cyano, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)C₁₋₄ alkyl, trifluoromethyl, halo, C(O)NHaryl, and C(O)NHheteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; each R⁷ is independently chosen from hydrogen, CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, aryl, and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁸ is chosen from hydrogen, C₁₋₄ alkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylheteroarylaryl, C₃₋₇ cycloalkyl, C₃₋₇ heterocycle, OH, OC₁₋₄ alkyl, C₁₋₄ alkylOC₁₋₄ alkyl, NH₂, NHC₁₋₄ alkyl, N(C₁₋₄ alkyl)₂, heterocycle, aryl and heteroaryl wherein aryl and heteroaryl may be optionally substituted with one or more R⁹; R⁹ is chosen from hydrogen, C₁₋₄ alkyl, CN, CF₃, C(O)Me, C(O)NH₂, and aryl; and m is chosen from 1 and
 2. 16. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
 17. (canceled)
 18. (canceled)
 19. (canceled)
 20. (canceled)
 21. (canceled)
 22. (canceled)
 23. (canceled)
 24. (canceled)
 25. (canceled)
 26. (canceled)
 27. (canceled)
 28. (canceled)
 29. A compound according to claim 1, which is a compound selected from the group consisting of: (R)-5-((1-(2-chloroacetyl)piperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; (R)-5-((1-acryloylpiperidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one; and (R)-5-((1-acryloylpyrrolidin-3-yl)amino)-[3,4′-bipyridin]-6(1H)-one. 